前癃通胶囊对良性前列腺增生的临床观察和大鼠前列腺IGF-ⅠmRNA/IGF-ⅠRmRNA、Fas/Fas1表达的影响
|
摘要
背景：
良性前列腺增生是中老年男性的常见病、多发病。随着老龄人口日趋增加,良性前列腺增生的发病率不断攀升,其已成为严重影响中老年男性身心健康和生活质量的重大疾病。
目的：
观察前癃通胶囊治疗良性前列腺增生的临床疗效,探讨良性前列腺增生的基本病机以及前癃通胶囊对良性前列腺增生的作用机制,为前癃通胶囊治疗良性前列腺增生提供科学依据,以便更好地推广应用。
方法：
1.临床观察：74例良性前列腺增生患者,随机分为治疗组37例和对照组37例,治疗组口服前癃通胶囊,对照组口服前列舒乐胶囊。观察患者治疗前后国际前列腺症状评分(Ⅰ-PSS)、生活质量(QOL)评分、最大尿流率(Qmax)、平均尿流率(Qave)、膀胱残余尿(RUV)、中医症状评分和前列腺体积(PV)等的变化。
2.动物实验：72只SD雄性大鼠随机分为6组：正常组、模型组、前列舒乐胶囊组、前癃通胶囊低剂量组、前癃通胶囊中剂量组和前癃通胶囊高剂量组,每组12只。除正常组外,其余大鼠去势后皮下注射丙酸睾丸酮致前列腺增生法造模。分别灌胃给药30d后,处死大鼠取出前列腺并测湿重、体积和计算指数；RT-PCR法检测前列腺组织IGF-ⅠmRNA、IGF-ⅠRmRNA (?)勺表达；免疫组织化学染色法检测前列腺组织Fas、Fas1的表达。
结果：
1.临床研究：①前癃通胶囊治疗组和前列舒乐胶囊对照组均能明显降低BPH患者Ⅰ-PSS和QOL评分(P<0.01)；前癃通胶囊组降低Ⅰ-PSS、QOL评分优于前列舒乐胶囊组(P<0.05)。②两组均能明显提高BPH患者Qmax、Qave(P<0.01),前癃通胶囊组优于前列舒乐胶囊组(P<0.05)。③两组均能明显降低BPH患者RUV、PV(P<0.01),前癃通胶囊组优于前列舒乐胶囊组(P<0.05)。④两组均能明显缩小BPH患者前列腺内腺纵径(P<0.05),前癃通胶囊组和前列舒乐胶囊组无明显差异(P>0.05)。⑤两组均能明显改善BPH患者排尿困难、夜尿次数、尿线情况、倦怠乏力和少腹症状(P<0.01)；前癃通胶囊组改善排尿困难、夜尿次数、尿线情况优于前列舒乐胶囊组(P<0.05)；两组改善倦怠乏力和少腹症状无差异(P>0.05)。⑥前癃通胶囊组显效率61.8%,总有效率为88.2%；对照组显效率32.3%,总有效率为74.2%；前癃通胶囊组疗效优于前列舒乐胶囊组((P<0.05)。⑦两组对治疗前后血清总前列腺特异性抗原(tPSA)和勃起功能国际指数(IIEF-5)评分均无明显影响。
2.实验研究：①前癃通各剂量组、舒乐组大鼠前列腺湿重、体积和指数均小于模型组(P<0.01)；前癃通高剂量组降低前列腺湿重、体积和指数优于舒乐组(P<0.05)。②前癃通各剂量组、舒乐组大鼠前列腺组织IGF-ⅠmRNA、IGF-ⅠRmRNA的表达明显低于模型组(P<0.01)；前癃通高剂量组大鼠前列腺组织IGF-ⅠmRNA、IGF-ⅠRmRNA的表达低于前列舒乐组(P<0.05)。③前癃通各剂量组、舒乐组大鼠前列腺组织Fas、Fas1蛋白的表达明显高于模型组(P<0.01)；前癃通高剂量组大鼠前列腺组织中Fas、Fas1的表达高于舒乐组(P<0.05)。
结论：·
1.气虚血瘀是BPH的基本病机,益气活血、利水消癥为治疗大法。
2.前癃通胶囊能降低BPH患者国际前列腺症状评分和生活质量评分,提高最大尿流率和平均尿流率,减少膀胱残余尿量,改善中医症状和缩小前列腺体积。
3.前癃通胶囊能够降低实验性BPH大鼠前列腺湿重、体积和指数；能够降低实验性BPH大鼠前列腺组织IGF-ⅠmRNA、IGF-ⅠRmRNA的表达；能够提高实验性BPH大鼠前列腺组织Fas、FasⅠ的表达。实验结果提示,前癃通胶囊治疗良性前列腺增生的作用是多环节、多靶点的,影响前列腺组织IGF-ⅠmRNA、IGF-ⅠRmRNA和Fas、Fas1的表达可能是其中的机理之一
Backgroud:
Benign prostatic hyperplasia(BPH) is a common and frequently occurring disease of senile male. With the growing number of aged population,the incidence of BPH is also rising. BPH has become a major disease with serious influence on senile male's physical and mental health and quality of life.
Objective:
To investigate the clinical effect and mechanism of Qianlong Tong Capsule(QLTC) on BPH, to probe into the traditional chinese medical pathogenesis of BPH and support the capsule with scientific basis, so as to be better popularized and applied.
Methods:
1. Clinical study:74 cases of BPH were randomly divided into treatment group and control group. The cases were treated respectively by Qianlong Tong Capsule (QLTC) and Qianlie Shule Capsule (QLSLC) for 3 months. Changes of international prostate symptom scores (Ⅰ-PSS), quality of life(QOL) seores, TCM symtomatic scores, maximun flow rate(Qmax), average flow rate (Qave), bladder residual urine (RUV), and total prostate volume (PV) in patients with BPH were observed before and after treatment.
2. Animal experiment:72 SD male rats were randomly divided into six groups:normal group, model group, QLSLC group, QLTC low-dosage group, QLTC medium-dosage group, QLTC large-dosage group. Except for normal group, rats of the rest groups were established by subcutaneously injecting testosterone propionate after being castrated. The rats were killed and prostate glands were removed after intragastric achainistration respectively for 30 days. The weight, volume and index of the prostate were measured.By means of RT-PCR, the expressions of IGF-ⅠmRNA、IGF-ⅠRmRNA were examined in the prostates of rats. By means of immunohistochemisty the expressions of Fas, Fasl were examined in the prostates of rats.
Results:
1. Clinical study:After 3 months'treatment,①the levels ofⅠ-PSS and QOL seores in patients with BPH were reduced significantly in the treated group by QLTC and the control group by QLSLC(P<0.01). In respect of reducing the levels ofⅠ-PSS and QOL seores, QLTC superior to QLSLC (P<0.05).②QLTC and QLSLC improved significantly the levels of Qmax and Qave(P<0.01), QLTC superior to QLSLC(P<0.05).③QLTC and QLSLC reduced significantly the levels of RUV and PV (P<0.01), QLTC superior to QLSL (P<0.05).④QLTC and QLSLC reduced the longitudinal diameter of prostate significantly(P<0.05), but QLTC and QLSLC had no significantly difference (P>0.05).⑤QLTC and QLSLC reduced significantly the levels of dysuria, nocturia number, urine line, languid, the lower abdomen symptoms seores (P<0.01). QLTC reduced the levels of dysuria, urine line and nocturia number seores superior to QLSLC (P<0.05). But QLTC reduced the levels of languid, the lower abdomen symptoms seores had no significantly difference to QLSLC (P>0.05).⑥The markedly effective rate, total effective rate in the treated group was 61.8%,88.2% respectively, the markedly effective rate, total effective rate in the control group was 32.3%,74.2% respecti-vely. The curative effects of QLTC superior to QLSLC(P<0.05). ⑦QLTC and QLSLC both have little influence on tPSA and IIEF-5(P>0.05).
2. Animal experiment:①Copared with model group, prostatic weights, volumes and indexs decreased significantly in all of QLTC group and QLSLC group(P<0.01). Prostatic weights, volumes and indexs in QLTC large-dosage groups were less than QLSLC group (P<0.05).②Compared with model group, the expressions of IGF-ⅠmRNA and IGF-ⅠRmRNA decreased signifieantly in all QLTC and QLSLC groups(p<0.01). Compared with QLSLC, the expressions of IGF-ⅠmRNA and IGF-ⅠRmRNA in QLTC large-dosage groups groups decreased significantly (p<0.05).③The expressions of Fas and Fasl in QLTC varied dose group and QLSLC group were significantly more than model group (p<0.01), the expressions of Fas and Fasl in QLTC were significantly more than QLSLC group (p<0.05).
Conclusions:
1. Deficiency of Qi and blood stasis is the basic pathogenesis of BPH. The treatment of invigorating Qi and promoting blood flow and Lishui Xiaozheng were selected.
2.QLTC can effectively reduce the levels ofⅠ-PSS and ameliorated quality of life, improve the levels of Qmax and Qave, redue the levels of RUV, ameliorat the symptom of TCM, lessen PV.
3. QLTC shows multiway and multitarget treatment effects on BPH in experimental rats. QLTC can effectively decrease prostatic weights, volumes and indexs, decrease the expressions of IGF-ⅠmRNA and IGF-ⅠRmRNA, increase the expressions of Fas and Fasl in experimental rats. Experimental results indicated that the treatment of QLTC on benign prostatic hyperplasia is many links and targets, influence of the expression of IGF-ⅠmRNA、IGF-ⅠRmRNA、Fas and Fasl in prostate tissue might be one of the mechanisms.
良性前列腺增生是中老年男性的常见病、多发病。随着老龄人口日趋增加,良性前列腺增生的发病率不断攀升,其已成为严重影响中老年男性身心健康和生活质量的重大疾病。
目的：
观察前癃通胶囊治疗良性前列腺增生的临床疗效,探讨良性前列腺增生的基本病机以及前癃通胶囊对良性前列腺增生的作用机制,为前癃通胶囊治疗良性前列腺增生提供科学依据,以便更好地推广应用。
方法：
1.临床观察：74例良性前列腺增生患者,随机分为治疗组37例和对照组37例,治疗组口服前癃通胶囊,对照组口服前列舒乐胶囊。观察患者治疗前后国际前列腺症状评分(Ⅰ-PSS)、生活质量(QOL)评分、最大尿流率(Qmax)、平均尿流率(Qave)、膀胱残余尿(RUV)、中医症状评分和前列腺体积(PV)等的变化。
2.动物实验：72只SD雄性大鼠随机分为6组：正常组、模型组、前列舒乐胶囊组、前癃通胶囊低剂量组、前癃通胶囊中剂量组和前癃通胶囊高剂量组,每组12只。除正常组外,其余大鼠去势后皮下注射丙酸睾丸酮致前列腺增生法造模。分别灌胃给药30d后,处死大鼠取出前列腺并测湿重、体积和计算指数；RT-PCR法检测前列腺组织IGF-ⅠmRNA、IGF-ⅠRmRNA (?)勺表达；免疫组织化学染色法检测前列腺组织Fas、Fas1的表达。
结果：
1.临床研究：①前癃通胶囊治疗组和前列舒乐胶囊对照组均能明显降低BPH患者Ⅰ-PSS和QOL评分(P<0.01)；前癃通胶囊组降低Ⅰ-PSS、QOL评分优于前列舒乐胶囊组(P<0.05)。②两组均能明显提高BPH患者Qmax、Qave(P<0.01),前癃通胶囊组优于前列舒乐胶囊组(P<0.05)。③两组均能明显降低BPH患者RUV、PV(P<0.01),前癃通胶囊组优于前列舒乐胶囊组(P<0.05)。④两组均能明显缩小BPH患者前列腺内腺纵径(P<0.05),前癃通胶囊组和前列舒乐胶囊组无明显差异(P>0.05)。⑤两组均能明显改善BPH患者排尿困难、夜尿次数、尿线情况、倦怠乏力和少腹症状(P<0.01)；前癃通胶囊组改善排尿困难、夜尿次数、尿线情况优于前列舒乐胶囊组(P<0.05)；两组改善倦怠乏力和少腹症状无差异(P>0.05)。⑥前癃通胶囊组显效率61.8%,总有效率为88.2%；对照组显效率32.3%,总有效率为74.2%；前癃通胶囊组疗效优于前列舒乐胶囊组((P<0.05)。⑦两组对治疗前后血清总前列腺特异性抗原(tPSA)和勃起功能国际指数(IIEF-5)评分均无明显影响。
2.实验研究：①前癃通各剂量组、舒乐组大鼠前列腺湿重、体积和指数均小于模型组(P<0.01)；前癃通高剂量组降低前列腺湿重、体积和指数优于舒乐组(P<0.05)。②前癃通各剂量组、舒乐组大鼠前列腺组织IGF-ⅠmRNA、IGF-ⅠRmRNA的表达明显低于模型组(P<0.01)；前癃通高剂量组大鼠前列腺组织IGF-ⅠmRNA、IGF-ⅠRmRNA的表达低于前列舒乐组(P<0.05)。③前癃通各剂量组、舒乐组大鼠前列腺组织Fas、Fas1蛋白的表达明显高于模型组(P<0.01)；前癃通高剂量组大鼠前列腺组织中Fas、Fas1的表达高于舒乐组(P<0.05)。
结论：·
1.气虚血瘀是BPH的基本病机,益气活血、利水消癥为治疗大法。
2.前癃通胶囊能降低BPH患者国际前列腺症状评分和生活质量评分,提高最大尿流率和平均尿流率,减少膀胱残余尿量,改善中医症状和缩小前列腺体积。
3.前癃通胶囊能够降低实验性BPH大鼠前列腺湿重、体积和指数；能够降低实验性BPH大鼠前列腺组织IGF-ⅠmRNA、IGF-ⅠRmRNA的表达；能够提高实验性BPH大鼠前列腺组织Fas、FasⅠ的表达。实验结果提示,前癃通胶囊治疗良性前列腺增生的作用是多环节、多靶点的,影响前列腺组织IGF-ⅠmRNA、IGF-ⅠRmRNA和Fas、Fas1的表达可能是其中的机理之一
Backgroud:
Benign prostatic hyperplasia(BPH) is a common and frequently occurring disease of senile male. With the growing number of aged population,the incidence of BPH is also rising. BPH has become a major disease with serious influence on senile male's physical and mental health and quality of life.
Objective:
To investigate the clinical effect and mechanism of Qianlong Tong Capsule(QLTC) on BPH, to probe into the traditional chinese medical pathogenesis of BPH and support the capsule with scientific basis, so as to be better popularized and applied.
Methods:
1. Clinical study:74 cases of BPH were randomly divided into treatment group and control group. The cases were treated respectively by Qianlong Tong Capsule (QLTC) and Qianlie Shule Capsule (QLSLC) for 3 months. Changes of international prostate symptom scores (Ⅰ-PSS), quality of life(QOL) seores, TCM symtomatic scores, maximun flow rate(Qmax), average flow rate (Qave), bladder residual urine (RUV), and total prostate volume (PV) in patients with BPH were observed before and after treatment.
2. Animal experiment:72 SD male rats were randomly divided into six groups:normal group, model group, QLSLC group, QLTC low-dosage group, QLTC medium-dosage group, QLTC large-dosage group. Except for normal group, rats of the rest groups were established by subcutaneously injecting testosterone propionate after being castrated. The rats were killed and prostate glands were removed after intragastric achainistration respectively for 30 days. The weight, volume and index of the prostate were measured.By means of RT-PCR, the expressions of IGF-ⅠmRNA、IGF-ⅠRmRNA were examined in the prostates of rats. By means of immunohistochemisty the expressions of Fas, Fasl were examined in the prostates of rats.
Results:
1. Clinical study:After 3 months'treatment,①the levels ofⅠ-PSS and QOL seores in patients with BPH were reduced significantly in the treated group by QLTC and the control group by QLSLC(P<0.01). In respect of reducing the levels ofⅠ-PSS and QOL seores, QLTC superior to QLSLC (P<0.05).②QLTC and QLSLC improved significantly the levels of Qmax and Qave(P<0.01), QLTC superior to QLSLC(P<0.05).③QLTC and QLSLC reduced significantly the levels of RUV and PV (P<0.01), QLTC superior to QLSL (P<0.05).④QLTC and QLSLC reduced the longitudinal diameter of prostate significantly(P<0.05), but QLTC and QLSLC had no significantly difference (P>0.05).⑤QLTC and QLSLC reduced significantly the levels of dysuria, nocturia number, urine line, languid, the lower abdomen symptoms seores (P<0.01). QLTC reduced the levels of dysuria, urine line and nocturia number seores superior to QLSLC (P<0.05). But QLTC reduced the levels of languid, the lower abdomen symptoms seores had no significantly difference to QLSLC (P>0.05).⑥The markedly effective rate, total effective rate in the treated group was 61.8%,88.2% respectively, the markedly effective rate, total effective rate in the control group was 32.3%,74.2% respecti-vely. The curative effects of QLTC superior to QLSLC(P<0.05). ⑦QLTC and QLSLC both have little influence on tPSA and IIEF-5(P>0.05).
2. Animal experiment:①Copared with model group, prostatic weights, volumes and indexs decreased significantly in all of QLTC group and QLSLC group(P<0.01). Prostatic weights, volumes and indexs in QLTC large-dosage groups were less than QLSLC group (P<0.05).②Compared with model group, the expressions of IGF-ⅠmRNA and IGF-ⅠRmRNA decreased signifieantly in all QLTC and QLSLC groups(p<0.01). Compared with QLSLC, the expressions of IGF-ⅠmRNA and IGF-ⅠRmRNA in QLTC large-dosage groups groups decreased significantly (p<0.05).③The expressions of Fas and Fasl in QLTC varied dose group and QLSLC group were significantly more than model group (p<0.01), the expressions of Fas and Fasl in QLTC were significantly more than QLSLC group (p<0.05).
Conclusions:
1. Deficiency of Qi and blood stasis is the basic pathogenesis of BPH. The treatment of invigorating Qi and promoting blood flow and Lishui Xiaozheng were selected.
2.QLTC can effectively reduce the levels ofⅠ-PSS and ameliorated quality of life, improve the levels of Qmax and Qave, redue the levels of RUV, ameliorat the symptom of TCM, lessen PV.
3. QLTC shows multiway and multitarget treatment effects on BPH in experimental rats. QLTC can effectively decrease prostatic weights, volumes and indexs, decrease the expressions of IGF-ⅠmRNA and IGF-ⅠRmRNA, increase the expressions of Fas and Fasl in experimental rats. Experimental results indicated that the treatment of QLTC on benign prostatic hyperplasia is many links and targets, influence of the expression of IGF-ⅠmRNA、IGF-ⅠRmRNA、Fas and Fasl in prostate tissue might be one of the mechanisms.
引文
[1]郭应禄,胡礼泉.男科学[M].北京：人民卫生出版社,2005,1494
[2]顾方六.现代前列腺病学[M].北京：人民军医出版社,2002,53
[3]Kaplan SA,McConnell JD, Roehrborn CG, et al. Medical Therapy of Prostatic Symptoms (MTOPS) Research Group. Combination therapy wwith doxazosin and finasteride for benign prostatic hyperplasia in patients with lower urinary tract symptoms and a baseline total prostate volume of 25ml or greater[J]. J Urol,2006,175:217-220
[4]Djavan B, Chapple C, Milani S, et al. State of the art on the efficacy and tolerability of alphal- adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia[J]. Urology,2004,64: 1081-1088
[5]贺菊乔.前列腺疾病中西医诊治之我见[J].中医药导报,2005,11(1)：22-24
[1]杨勇译,郭应禄校.第五届国际良性前列腺增生咨询委员会国际科学委员会推荐意见：老年男性下尿路症状的评估和治疗[J].中华泌尿外科杂志,2001,22(9)：564-570
[2]郑筱萸.中药新药临床研究指导原则(试行)[M].北京：中国医药科技出版社,2002,305
[3]段登志,张鸿青,于玲.前列回春对实验性大鼠前列腺组织血管内皮生长因子表达的影响[J].中华男科学,2004,10(2)：152-154
[4]黄源鹏,杜建,洪振丰.康泉方对大鼠前列腺组织凋亡调控基因bax、bc1-2 mRNA表达的影响[J].中国中西医结合杂志,2007,27(8)：711-712
[5]陈奇.中药药理实验方法学[M].北京：人民卫生出版社,2006,93-95
[6]中医病证诊断疗效标准[S].南京：南京大学出版社,1994,144
[7]马卫国.癃必消胶囊对前列腺增生间质细胞作用机理的实验研究与临床观察[D].博士学位论文,2003,90
[8]张智琳.从肺论治男科病初探[J].中国医药学报,2004,8(19)：487-488
[9]夏忠诚,余国英,徐剑刚.温宣通淋方治疗良性前列腺增生30例[J].中国临床医生,2008,36(7)：44-45
[10]陈金荣,候思理.前列腺增生从气血痰水论治探讨[J].中国医药学报,1999,5(14)：48-50
[11]王振新.自拟三甲汤治疗急性尿缩留21例[J].四川中医,2001,19(8)：49
[12]赵建业,戴福寿.以活血法治疗前列腺增生症经验[J].福建中医药,2004,35(2)：21-22
[13]韩伍龙.从痰瘀论治前列腺增生症30例[J].四川中医,2001,19(10)：46
[14]叶科贵.辩证论治前列腺增生症67例[J].河南中医,2006,26(7)：43-44
[15]刘亮.补气化瘀法治疗前列腺增生继发尿潴留[J].中国中医急症,2005,4(1)：378
[16]朱源北.补肾活血法治疗老年癃闭的体会[J].黑龙江中医药,2006,7(4)：28
[17]李富玉,许彦来,张少林.自制路通颗粒治疗老年前列腺增生症63例[J].实用医药杂志,2007,1(24)：64-65
[18]资桂平.益癃汤治疗前列腺增生症例临床观察[J].湖南中医药报,2003,9(6)：37-38
[19]黄源鹏,吴锦发.中医络病理论与良性前列腺增生关系探析[J].中华中医药杂志,2006,1(21)：45-46
[20]张亚大,卢子杰,张平,等.益肾逐瘀汤治疗良性前列腺增生30例疗效观察[J].南京中医药大学学报(自然科学版),2001,17(4)：216-217
[21]王晓春.补肾化瘀散结汤治疗前列腺增生76例[J].河北中医,2007,29(1)：50
[22]马晓勇,陈丽君.温肾化瘀法治疗前列腺增生48例[J].陕西中医,2000,21(10)：442
[23]王劲松.前列腺增生症论治五法[J].四川中医,2000,12(18)：11-12
[24]郭明福.开利散结汤治疗前列腺增生110例[J].江苏中医药,2003,24(3)：34
[25]谢昌仁.名老中医治疗良性前列腺增生经验荟萃[J].中国临床医生,2006,4(34)：57-59
[26]蓝毕生.通补奇经方治疗良胜前列腺增生症32例[J].吉林中医药,2002,22(3)：191
[27]胡臻.升阳通络汤治疗前列腺增生症20例[J].中国中医药信息杂志,2002,9(9)：53
[28]何红兵.从瘀辩证分型治疗老龄前列腺增生症72例[J].安徽中医临床杂志,2001,13(3)：181
[29]贺菊乔.前列腺疾病中西医诊治之我见[J].中医药导报,2005,11(1)：22-24
[30]郭应禄,胡礼泉.男科学[M].北京：人民卫生出版社,2005,1495-1496
[31]willson JD. The pathogenesis of benign proztatl chyperplasia[J]. Am J cd 1980; 68:745
[32]Lu ML, Schneider MC, Zheng Y, et al. Caveolin-1 interacts with androgen receptor. A positive modulator of androgen receptor mediated transactivation[J]. J Dial Client,2001,276:13442-13451
[33]Steers WD.5 alpha-reductase activity in the prostate[J]:Urology,2001,58(6 Suppl 1):17-24
[34]Xia SJ,Xu CX, Tang XD,et al. Apoptosis and hormonal milieu in ductalsystem of normal prostate and benign prostatic hyperplasia[J]. Asian J An-drol,2001,3:131-134
[35]吴荃,肖向茜,刘树业,等.雌二醇通过调节上皮细胞系的旁分泌促进前列腺间质细胞 增殖和分化[J].中国病理生理杂志,2007,23(7)：1382-1387
[36]Michaud L B. Adjuvantuse of aromatase inhibitors in postmenopausal women with breast cancer[J]. Am J Health Systpharm,2005,62(3):266-273
[37]Monti S, Di SilverioF, IraciR, etal. Regional variations of insulin-like growth factor Ⅰ (IGF-Ⅰ), IGF-Ⅱ, and receptor type Ⅰ in benign prostatic hyperplasia tissue and their correlation with intraprostatic androgens[J]. Clin Endocrinol Metab, 2001,86(4):1700-1706
[38]Royuela M, de Miguel MP,Bethencourt FR, et al. Estrogen receptors alpha and beta in the normal, hyperplastic and careinamatous human protate[J]. J Endocrinol, 2001,168(3):447-454
[39]Salazar EL, Mercado E, Calzada L. Prostatic cancer/benign prostatic hypertrophy. Subcellular distribution of estradiol/androgen receptors[J]. Arch Androl,2005, 51 (2):135-139
[40]Smith P.Rhodes NP,Ke Y.Foster CS. Relationship between upregulated oestrogen receptors and expression of growth factors incultured, human, prostatic stromal cells exposed to estradiol or dihydrotestosterone[J]. Prostate Cancer Prostatic Dis,2004, 7(1):57-62
[41]Smith P.Rhodes NP, Ke Y.Foster CS. Upregulation of estrogen and androgen receptors modulate expression of FGF-2 and FGF-7 in human, cultured, prostatic stromal cells exposed to high concentrations of estradiol[J]. Prostate Cancer Prostatic Dis,2002,5(2):105-110
[42]Habermann H, Ray V,Habermann W, et al. Alterations in gap junction protein expression in human benign prostatic hyperplasia and prostate cancer[J].J Urol, 2002,167 (2Ptl):655-660
[43]叶烈夫,张元芳,方祖军,等.5 a-还原酶在良胜增生前列腺组织中的表达及意义[J].中华医学杂志,2003,83(15)：1296-1299
[44]Steers WD.5 alpha-reductase activity in the prostate [J]. Urology,2001,58(6):17-24
[45]Carballido, Rodriguez, Rodriguez Vallejo, et al. Benign prostatic hyperplasia and Evidence based medicine:itsapproach in clinical practice[J]. MedClin(Barc), 2000,114(SuPP12):96-104
[46]郭应禄,胡礼泉.男科学[M].北京：人民卫生出版社,2005,1496-1497
[47]Sciarra F, Toscano V. Role of estrogens in human prostatic hyperplasia[J]. Areh Androl,2000,44(3):213-220
[48]谢庆祥,汪鸿,林福地,等.生长调控因子异常与良性前列腺增生的关系[J].中华泌尿外科杂志,2001,22(9)：520-522
[49]Story MT, Hopp KA, Meier DA, et al. Influence of transforming growth factor β 1 and other growth factors on basic fibroblast growth factor level and proliferation of cultured human prostated-derived fibroblast[J]. The Prostate,1993,22(4):183
[50]Gleason PE, Jones JA, Regan JA, et al. Platelet derived growth factor, androgens and imf lammation:possible ecology factors in the development of prostatic hyperplasia[J]. J Urol,1993,149(12):1586
[51]Funa K, Nordgren H, Nilsson S, In expression of mRNA for Proseongenes in benign Prostatic hyprerplasia[J]. Scand J Urol Nephrol,1991,25(2):95
[52]那彦群,郭震华.实用泌尿外科学[M].北京：人民卫生出版社,2009,387-388
[53]Jacoba SC. Story MT, Sasse J, et al. Charaeterization of growth factors derived From the rat ventral prostate[J]. J Urol,1988,139(11):1106
[54]Story MT, Vingaton B, Baeten L, et al. Cultured human prostate-derived fibroblasta produce a factor that accumulate their growth with Proper f ies in distinguiehable from basic fibroblast growth factor[J]. Prostate,1989,15(7):355
[55]Sinowatz F, Schams D, Einspanier R, et al. Cellular localization of fibroblast growth factor 2(FGF-2) in beign prostatic hyperplasia[J]. Histopathol,2000,15: 475
[56]闫爰中,曾照锦,张治国,等.前列腺组织中EGF、bFGF的表达[J].临床泌尿外科杂志,2001,16(1)：27-29
[57]Dow JK, Vere White RW, Fibroblast growth factor2:its structure and property, paracrine function, tumor angiogenesis, and prostate-related mitogenic and oncogeniic functions[J]. urology,2000,55:800
[58]Morris GL, Dodd JG. Epidermat growth factormRNA levels in human prostate tumors And cell lines[J].J Urol,1990,143(3):127
[59]Gann PH, Klein KG, Chatterton RT, et al. Growth factors in expressed prostatic fluid from men with prostate cancer, BPH, and clinically normal prostates[J]. Prostate, 1999,40(41):248-55
[60]贾彬,蔡文清,黎玮,等.表皮生长因子对小鼠前列腺细胞增殖凋亡的影响[J].河北医科大学学报,2005,26(3)：204-205
[61]Grorge KI, Billie-Jo MK, James AM, et al. Differential immunoreactivity of epidermal growth factor receptor in benign,dysplastic and malignant prostatic tissues[J]. J Urol,1993,14(9):170-173
[62]Sherwood ER, Lee C. Epidermal growth factor-related peptides and the epidermal growth factor receptor in normal and malignantprostate[J]. World J Urol,1995,13 (5):290
[63]Ibrahim GK, MaeDonald JA, Ibrahim SN, et al. Differential immunoreactivity of Epidermal growth factor receptor in benign, clysplastic and malignant prostatic Tissues[J]. J Urot,1993,149(4):170
[64]SixtinaGL, Diez SG, Hi jazi A, et al. Inereased basal Cell prolifereroPhy and EGF receptor exceptor expression in benign hypertrophy compared to normal prostate [J].J Urol,1993,149(5):243
[65]Ftydrenberg M, Foo TM, Jones AS, et al. Benign prostatic hyplasia-video image analyais and its relationship to androgen and epidermal growth faetor recptorexpression [J].J Urol,1991,146(10):872
[66]贾彬,汤泓,黎玮,等.表皮生长因子对小鼠前列腺细胞雌雄激素受体表达的影响[J].南方医科大学学报,2006,26(10)：1473-1475
[67]韩丽华,孙佩杰,王和,等.表皮生长因子受体和雄激素受体在前列腺增生及其前列腺癌组织中的表达[J].中国临床康复,2005,9(18)：138-139
[68]Seiarra F, Monti S, Adamo MV, et al. Regional distribution of epidermal growth factor, testosterone and dihydrotestosterone in benign prostatie hyperplasia tissue[J]. Urol Res,1995,23:387-390
[69]Marti kainen P, Ky Prianou N, Isaaes JT, et al. Effect of transforming grow factor-Ion proliferation and death of rat prostatic cells[J]. Endoerinology,1990, 127(12):296-297
[70]Wilding G. Response of prostate cancer cells to peptide grow factors:transforming growth factor-beta[J]. Cancer Surv,1991,11(2):147
[71]Massague J. Effect of transforming growth factor in human prostate[J]. J Biol Chem,1990,265 (21):393
[72]PeehlDM, RG Sellers. Basic FGF, EGF, and PDGF Modify TGF-β1 induction of smooth muscle cell phenotype in human prostatic stromal cells[J]. Prostate,1998,35(2): 125-134
[73]Ilio KY, Park II, PinsMR, et al.Apoptotic activity of doxazosin on prostate stromain vitrois mediated through an autocrine expression of TGF-betal[J]. Prostate, 2001,48(3):131-135
[74]Zhou W, Park I, PinsM, et a.1 Dual regulation of proliferation and growth arrest in prostatic stromal cells by transforming growth factor-β1[J]. Endocrinology, 2003,144(10):4280-4284
[75]吴荃,肖向茜,刘树业.雌二醇通过调节上皮细胞系的旁分泌促进前列腺间质细胞增殖和分化[J].中国病理生理杂志,2007,23(7)：1382-1387
[76]Hsing AY, Kadomatsu K,Bonham MJ,et al. Regulation of apoptosis induced byTGF-β1 in nontumorigenic & tumorigenic rat prostatic epithelial cell lines[J]. Camcer res,1996,56:5146-5150
[77]Ilio KY, Sensibar JA, Lee C. Effect of TGF-β1, TGF-αand EGFon cell proliferation &cell death in rat vental prostaic epithelial cells in culture[J].J Adrol,1995,16: 482-490
[78]Peehl DM, Sellers RG. Basic FGF, EGF and PDGF modify TGF-β-induction of smooth m uscle cellphenotype in human prostatic stromal cells [J]. Prostate,1998,35 (2) :125-134
[79]牛远杰,张琚,马腾骧,等TGF-β1, bFGF对前列腺基质细胞增殖和分化的影响[J].中华泌尿外科杂志,1999,20(12)：749-752
[80]UntergasserG, Gander R, Lilg C, et al. Profiling molecular targets of TGF-betal in prostate fibroblast to myofibroblast transdifferentiation [J]. Mech Ageing Dev,2005,126(1):59-69
[81]Story MT, Hopp KA, Meier DA, et al. Influence of transforming growth factor β1 and other growth factors on basic fibroblast growth factor level and prolife ration of cultured human prostated-derived fibroblast[J]. The Prostate,1993, 22(4):183
[82]王建业,左涛,万奔.体外转化生长因子1与表皮生长因子对人前列腺上皮细胞增殖的作用调节[J].中老年医学杂志,2001,20(4)：255-256
[83]牛远杰,张琚,马腾骧,等TGF-β1/bFGF对前列腺基质细胞增殖和分化的影响[J].中华泌尿外科杂志,1999,20：749-752
[84]Kerr JFR, Wylie AH. Curri.e AR. Apoptosis:a basic biological phenomenon with wide-ranging implications in tissue kinetics[J]. Br J Caneer,1972,26:239-257
[85]杨金瑞,黄循,杨竹林.前列腺增生和前列腺癌组织细胞凋亡及bcl-2、bax基因表达的研究[J].中华泌尿外科杂志,2000,21(8)：485-487
[86]石建党,李江峰,杨洪波,等.良性前列腺增生组织中基质细胞的增殖和凋亡[J].中国病理生理杂志,2005,21(4)：817-819
[87]邓方明,顾方六,夏同礼,等.人良性前列腺增生细胞增殖和凋亡状态的研究[J].中华外科杂志,1996,34(10)：620-622
[88]邵强,马骏,张玉海,等.良性前列腺增生不同区带的细胞增殖和凋亡状态的研究[J].中华泌尿外科杂志,2001,22(3)：164-166
[89]杨金瑞,黄循.前列腺疾病细胞凋亡及Bcl-2/Bax, Fas/Fasl调控研究[J].国外医学·泌尿系统分册,2000,20(4)：149
[90]胡野,凌志强,单小云.细胞凋亡的分子医学[M].第1版.北京：军事科学出版社,2002,8(1)：3-9
[91]Royuela M, De Miguel MP. Bethencourt FR, et al. bcl-2 its reeeptors. And bcl-2 and bax genes in normal. Hyperplastic and carcinomatous humanprostates:Immunohi-stochemical comparative analysis[J].Growth Faetors,2000,18(2):135-146
[92]Hegarty Paul K, Watson R. William G, et al. Effeets of cyclic stretch on prostatic cells in culture[J]. J Urol,2002,168(5):2291-2295
[93]Badawi. Alaa F, liu yin yin. Eledden, Mazen B, et al. Age-assoeiated changes in the expression Pattem of cyclooxygenase-2 and related Apoptotic markers in the cancer susceptible region of rat prostate [J]. Carcinogenesis,2004,25(9):1681-1688
[94]Wang W. Bergh A. Damber JE. Chronic inflammation in benign prostate hyperplasia is associated with focal upregulation of cyclooxygenase-2[J]. bcl-2 and cell proliferation in the glandular epithelium[J]. Prostate,2004,61(1):60-72
[95]贾彬,蔡文清,黎伟,等.雌激素对前列腺增生症移行区细胞bcl-2、bax和C-myc基因表达的影响[J].中华实验外科杂志,2004,21(1)：77-78
[96]王小峰,叶海云,姜辉,等.雄激素对良性前列腺增生组织中bcl-2mRNA表达的影响[J].中华外科杂志,2000,38(3)：198-200
[97]Cardillo M, Berchem G, Tarkington MA, et al. Resistance to apoptosis and up regulation of bcl-2 in benign prostatic hyperplasia after androgen deprivation[J]. J urol,1997,158:212-216
[98]Gandour-Edwards R. Mack PC. Devere-White RW, et al. Abnormalities ofApoptotic and cell cycle regulatory Proteins in distinct histopathologic components of benign prostatic hyperplasia[J]. Prostate Caneer Prostatie Dis,2004,17(10):1038-1041
[99]Mare Colombel, CarlA. 01ssom, et al. Hormone-regulated apoptosis results from reentry of differentiated prosate[J]. Cancer Res,1992,52:4313-4319
[100]Richard R, Berges. Yuzo Furuya, et al. cell proliferation DNA repair. And P53 function are not required for programmed death of prostatic glandular cells induced by androgen ablation[J]. Proc Natl Acad Sci USA,1993,90:8910-8914
[101]Shin S C B, Cho Y S. An antiapoptotic protein human survivin is a direct inhibtior of caspase-3 and-7[J].J Biochemistry,2001,40:1117-1123
[102]0'Neill A J, Boran S A,O' Keane C, et al. Caspase 3 expression in benign prostatic hyperplasia and prostate carcinoma[J]. Prostate,2001,47(3):183
[103]Soha J H, Kim D H, Choi N G, et al. Caspase-3/CPP 32 immunoreactivity and its correlation with frequency of apoptotic bodies in human prostatic carcinomos and benign nodular hyperplasias[J]. Histopathology,2003,37(6):555
[104]Shariat S F, Ashfaq R, Roehrborn C G, et al. Expression of survivin and apoptotic biomarkers in benign prostatic hyperplasia[J]. J Urol,2005,174:2046-2050
[105]邓春华,丘少鹏,陈辉熔,等Caspase-3在前列腺组织中的表达和意义[J].中华男科学杂志,2003,17(4)：224-228
[106]魏强.良性前列腺增生症的治疗[J].临床药物治疗杂志,2007,5(2)：18-21
[107]Kyprianou N, Litvak JP,Borkowski A, et al. Induction of prostate apoptosis by doxazosin in benign prostatic hyperplasia. J Urol,1998,159:1810-1815
[108]刘孝东,杨宇如,卢一平,等.非那雄胺减少TURP术中出血的机理研究[J].中华泌尿外科杂志,2003,24(10)：694-697
[109]RUVskewitz R, Girman CJ, Fowler J, et al. Effect of finasteride on bother and other health related quality of life aspects associated with benign prostatic hyperplasia[J]. Urology,1999,54:670-678
[110]Lepor H, Williford W0, Barry MJ, et al. The efficacy of terazosin, finasteride or both in benign prostatic hyperplasia. vete-rans affairs cooperative studies benign prostatic hyperplasia study group[J]. Nengl J Med,1996,335:533-539
[111]Kaplan SA.Long-term sustained improvement in sym ptoms of benign prostatic hyperplasia with the dual 5alpha-reductase inhibitor dutasteride:results of 4-year studies[J].J Urol,2006,175(6):2211-2212
[112]Mc connell JD, Ruvskewitz R, Walsh P, et al. the effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. finasteride long-term efficacy and safety study group[J]. Nengl j Med,1998,338:557-563
[113]Kaplan SA. Medical therapy in the management of bph. Progression versus symptoms [A]. Office education of 94th annual meeting aua,1999,44-45
[114]Hudson PB, Boake R, Trachtenberg J, et al. Efficiency of finasteride is maintained in patients with bph treated for 5 years[J]. Urology,1999,53:690-695
[115]陈光,臧文臣.黄芪多糖对动物肿瘤细胞凋亡影响的研究[J].中医药学报,2002(4)：30
[116]薛红漫,孟哲,郭海霞,等.黄芪浸膏粉诱导Jurkat clone E621细胞凋[J].中国实验诊断学,2005,8(4)：9
[117]李帆,梁敬钰.王不留行的研究进展[J].海峡药学,2007,19(3)：1-4
[118]劳爱娜,桑圣民.常用中药基础研究(第五章)[M].北京：高等教育出版社,2002,80-112
[119]吴金玉,黄雪霞,史伟,等.田七注射液对肾病综合征患者血脂及血液流病学的影响[J].广西医学,2005,27(12)：194-196
[120]张喜平,齐丽丽,刘达人.三七及其有效成分的药理作用研究现状[J].医学研究杂志,2007,36(4)：96-98
[121]谢新生,张秀丽.穿山甲煎液诱导HL-60细胞凋亡的研究[J].浙江中西医结合杂志,2001,11(8)：477-479
[122]刘京生,苗智慧,董力,等.水蛭抗肿瘤作用的实验研究[J].时珍国医国药,2001,12(10)：884-885.
[123]袁淑兰,王修杰.丹参酮抗肿瘤作用及其机理的研究[J].癌症,2003,22(12)：1363-1366.
[124]贾金铭.中国中西医结合男科学[M].北京：中国医药科技出版社,2005,304
[125]祁公任,陈涛.前列腺增生症中医临床疗效评价标准的探讨[J].江苏中医,1999,20(8)：7-8
[126]贾金铭.中国中西医结合男科学[M].北京：中国医药科技出版社,2005,302
[127]张岐山,郭应禄.泌尿系超声诊断学[M].北京：科学技术文献出版社,2001,292-293
[128]李诺,阮园,张慧娟.超声测定良性前列腺增生患者残余尿量的临床意义[J].徐州医学院学报,2009,29(8)：544-545
[129]吴阶平.吴阶平泌尿外科学[M].济南：山东科学技术出版社,2004,1134-1158
[130]武治津,张鹏,张居忠,等.良性前列腺增生患者膀胱出口梗阻及逼尿肌强度对剩余尿的影响[J].中华泌尿外科杂志,2002,23(9)：548-549
[131]周立群,陈为民,那彦群,等.良性前列腺增生与前列腺癌患者血清PSA水平与游离PSA比值的比较[J].中华泌尿外科杂志,2002,23(6)：354.
[132]Schulman CC. Lower urinary tract symptoms/benign prostatic hyperplasia: minimizing morbidity caused by treatment[J]. Urology,2003,62(3 Suppll):24-33
[133]Boyle P, Robertson C, Mazzetta C, et al. The association between lower urinary tract symptoms and erectile dysfunction in four centres:the UrEpik study[J]. BJU Int,2003,92:719-725
[134]McVary KT. Sexual dysfunction in men with lower urinary tract symptoms and benign hyperplasia:an meringlink[J]. BJU int,2003,91:770-771
[135]Pahlman S, Meyerson G, Lindgren E, et al. Insulin-like growth factor-I shifts from premoting cell division to potentiating maturation during neurona differentiation [J].Pnas,1991,88:99-104
[136]EI-Badry 0, Romanus J, Helman L, et al. Automous growth of a human neuroblastoma cell line is mediated by insulin-like growth factor-Ⅱ [J]. J Clin Invest,1989,84:829
[137]Kleinberg DL, R uan W, Yee D, et al. Insulin-like growth factor (IGF)-I controls prostate fibromuscular development:IGF-I inhibition prevents both fibromuscular and glandular development in eugonadal mice[J]. Endocrinology,2007,148(3):1080-1088
[138]Soulitzis N, Karyotis I, Delakas D, et al. Expression analysis of peptide growth factors VEGF, FGF2, TGFB1, EGF and IGF1 in prostate cancer and benign prostatic hyperplasia[J]. Int J Oncol,2006,29(2):305-314
[139]姜辉,朱积川,许清泉.雌、雄激素对前列腺中IGF-I基因表达的影响[J].中华泌尿 外科杂志,2000,21(4)：227-228
[140]Cui X S ong Y Jjun J H, et al. Insulin-like growth factor-I alters apoptosis related genes and reduces apoptosis in porcine parthenotes developing in vitro[J]. Theriogenology,2005,63(4):1070-1080
[141]Monti S, Di SilverioF, IraciR, etal. Regional variations of insulin-like growth factor Ⅰ (IGF-Ⅰ), IGF-Ⅱ, and receptor type Ⅰ in benign prostatic hyperplasia tissue and their correlation with intraprostatic androgens[J]. Clin Endocrinol Metab, 2001,86(4):1700-1706
[142]姜辉,朱积川,王晓峰,等.胰岛素样生长因子Ⅰ、Ⅱ与其受体mRNA在前列腺增生组织中表达[J].中华泌尿外科杂志,1997,18(9)：564-566
[143]姜辉,叶海云,许清泉,等.Bcl-2和IGF-Ⅰ mRNA在正常和增生前列腺组织中表达及意义[J].中国男科学杂志,2001,15(1)：20-22
[144]Grant ES, Ross MB, Ballard S, et al. The insulin-like growth factor type Ⅰ receptor stimulates growth and suppresses apoptosis in prostatic stromal cells[J]. J Clin Endocrinol Metab,1998,83(9):3252-3257
[145]Prayer-Galetti T, Rossi GP, Belloni AS. Gene expression and autographic localization of endothelin-1 and its receptors A and B in the different zones of the normal human prostate[J]. J Urol,1997,157:2334-2339
[146]Torring N, Vinter-Jensen L, Pedersen SB, et al. Systemic administration of insulin-like growth factor I (IGF-I) causes growth of the rat prostate[J], Urol, 1997,158(1):222-227
[147]Nagata S, Golstein P. The Fas death factor[J]. Seience,1995:267(5203):1449-1156
[148]郑佳,刘复强Fas/Fas1及其临床意义[J].首都医科大学报,2004,25(3)：411-414
[149]魏红山,李定国.细胞凋亡的信号转导机制与调节[J].国外医学分子生物学分册,2000,22(1)：27-31
[150]暨明,韦超凡.细胞凋亡启动与执行分子极其作用机制的研究进展[J].国外医学、生理、病理科学与临床分册,2001,21(2)：92-94
[151]Lee J, Richburg JH, Younkin SC etal. The Fas system is a key regulator of germ cell apoptosis in the testis. [J].Endocrinology.1997,138(5):2081-2088
[152]Kawakami A, Eguehi K. Involvement of apoptotic cell death in autoimmune diseases[J]. Med Electron Mierose,2002,35(1):1-8
[153]Philchenkov AA. CasPases as regulators of apoptosis and other cell functions [J]. Bioehemistry(Mose),2003,68 (4):365-376
[154]谢庆祥,汪鸿.前列腺组织中细胞凋亡调控基因的表达[J].临床泌尿外科杂志,2000,15(7)：320-321
[155]曹继刚,周安方,舒劲松,等.仙甲汤对实验性前列腺增生大鼠前列腺组织FAS蛋白表达的影响[J].现代中西医结合杂志,2008,17(6)：823-824
[156]段登志,于玲,张鸿青,等.前列回春对实验性大鼠前列腺组织Fas表达及细胞凋亡的影响[J].中国中药杂志,2003,(28)9：866-869
[157]Sasaki Y, Ahlned H. Takeuehi T, et al. Immunohistoehemical study of Fas. Fas ligand and inter leukin-1 converting enzyme expression in human prostatic cancer[J].Br J Urol,1998,81:852-855
[158]黄旭元,易彬,陈斌,等.BPH患者膀胱逼尿肌细胞凋亡及Fas、Fas1表达的研究[J].中国男科学杂志,2005,19(6)：18-20
[159]吴建辉,孙祖越,朱焰.去势Beagle犬前列腺增生模型的建立[J].中华男科学杂志,2003,9(6)：425-428
[160]陈晖,刘修恒,金化民.雌雄激素联用制作犬前列腺增生动物模型[J].临床泌尿外科杂志,2005,20(1)：44-46
[161]尚平,许宏等.性激素缓释硅胶囊对去势狗的激素替代作用[J].中国男科学杂志, 2000,14(2)：86-87
[162]Steiner MS, Couch RC, Stauffer D, et al. The chimpanzee as a model of human BPH[J]. J Urol,1999,162:1454-1461
[163]Tutrone RF, Ball RA, Ornitz DM, et al. Benign prostatic hyperplasia in a tranagenic mouse, a new hormonally hyperplasia sensitive inverstigatory model [J]. Urol,1993,149 (9):533
[164]张学军.bcl-2基因在良性前列腺增生中的作用[J].中华泌尿外科杂志,1997,18(2)：97-99
[165]余帆,宋波.尿生殖窦诱导的鼠前列腺增生模型制备[J].第三军医大学学报,1999,2(2)：131-132
[166]安军明.针刺对丙酸睾丸素所致小白鼠前列腺增生症疗效的实验观察[J].中国针灸,1998,18(6)：357
[167]孙伟桂,叶章群,米振国,等.改良简化的小鼠BPH模型及其特点[J].中国男科学杂志,2008,22(1)：24-27
[168]司瑜,王卫华,张金华,等.日龄对小鼠前列腺增生模型的影响[J].中国民康医学,2010,22(18)：2305,2332
[169]董佳晨,贾金铭,马卫国.癃闭消(消癃通闭)胶囊对BPH大鼠模型内皮素-1表达的影响[J].中国男科学杂志,2009,33(4)：35-38
[170]苗明三.对中医药研究中动物模型应用的探讨[J].河南中医药学刊,2000,15(1)：2-4
[171]叶建红.浅议中医证候动物模型制作[J].广西中医学院学报,2001,4(2)：79
[172]郭书文,孟庆刚,王硕仁.病证结合模型的研究思路[J].中医药学报,2001,29(1)：2-3
[173]冯毅翀,吴薇.对病证结合动物模型研制的一点看法和设想[J].现代中西医结合杂志,2005,14(8)：1112-1113
[174]张红宇,高菊珍,张晓华.补阳还五汤对气虚血瘀证大鼠血液流变学的影响[J].云南中医学院学报,2003,3(3)：10-11
[175]庞树玲,高金亮.中年大鼠气虚血瘀证的模拟及其机理探讨[J].天津中医学院学报,1997,16(3)：28-30
[1]Rosen C J, Pollak M. Circulating IGF-Ⅰ:New perspectives for a new century[J]. TEM,1999,10:136-141
[2]Frank SJ. Growth hormone, insulin-like growth factor Ⅰ, and growth:local knowledge[J]. Endocrinology,2007,148(4):1486-1488
[3]Klover P, Hennighausen L. Postnatal body growth is dependent on the transcription factors signal transducers andactivators of transcription 5a/b in muscle:a role for auto-crine/paracrine insulin-like growth factor-Ⅰ[J]. Endocrinology,2007,148 (4):1489-1497
[4]Pahlman S, Meyerson G,Lindgren E, et al. Insulin-like growth factor-Ⅰ shifts from premoting cell division to potentiating maturation during neurona differentiation [J]. Pnas,1991,88:99-104
[5]EI-Badry O, Romanus J, Helman L, et al. Automous growth of a human neuroblastoma cell line is mediated by insulin-like growth factor-Ⅱ [J]. J Clin Invest,1989,84:829
[6]Martin D, Feldman E. Regulation of insulin-like growth factor-Ⅱexpression andits role in autocrine growth of human neuroblastoma cells[J].J Cell Physiol,1993,15 5:290
[7]Barres B, Hart I, Co lesM,et al.Cell death and control of cell survival in the oligodendrocyte lineage[J]. Cell,1992,70:31
[8]Xu Zhe, Liu Fu-Kun, Qi Xiao-Ping, et al. The expression between insulin-like growth factor-Hand prognosis of colorectal patients[J]. Zhong Hua Wai Ke Zha Zhi,1999, 37(12):718-720
[9]Peters MG, Farias E, Colombo L, et al. Inhibition of invasion and metastasis by glypocan-3 in a syngeneic breast cancer model[J].B reast Cancer Res Treat,2003, 80(2):221-232
[10]Twigg S M, Baxter R C. IGF binding protein 5 forms an alternative ternary complex with IGFs and the acid lable subunit [J]. J Biol Chem,1998,273:6074-6079.
[11]Sarm a AV, Jaffe CA, Schottenf Eld D, et al. Insulin-like growth factor-1, insulin-like growth factor binding protein-3, and body mass index:clinical correlates of prostate volume among Black men [J]. Urology,2002,59(3):362-367
[12]Monti S, Di SilverioF, IraciR, et al. Regional variations of insulin-like growth factor Ⅰ (IGF-Ⅰ), IGF-Ⅱ, and receptor type Ⅰ in benign prostatic hyperplasia tissue and their correlation with intraprostatic androgens[J]. Clin Endocrinol Metab 2001,86 (4):1700-1706
[13]姜辉,朱积川,王晓峰,等.胰岛素样生长因子Ⅰ、Ⅱ与其受体mRNA在前列腺增生组织中表达[J].中华泌尿外科杂志,1997,18(9)：564-566
[14]姜辉,叶海云,许清泉,等.Bcl-2和IGF-Ⅰ mRNA在正常和增生前列腺组织中表达及意义[J].中国男利学杂志,2001,15(1)：20-22
[15]Kleinberg DL, R uan W, Yee D, et al. Insulin-like growth factor (IGF)-Ⅰ controls prostate fibromuscular development:IGF-Ⅰ inhibition prevents both fibromuscular and glandular development in eugonadal mice[J]. Endocrinology.2007,148(3):1080-1088
[16]Soulitzis N, Karyotis Ⅰ, Delakas D, et al. Expression analysis of peptide growth factors VEGF, FGF2, TGFB1, EGF and IGF1 in prostate cancer and benign prostatic hyperplasia[J]. Int J Oncol,2006,29(2):305-314
[17]姜辉,朱积川,许清泉.雌、雄激素对前列腺中IGF-Ⅰ基因表达的影响[J].中华泌尿外科杂志,2000,21(4)：227-228
[18]Cui X S ong Y.Jjun J H, et al. Insulin-like growth factor-Ⅰ alters apoptosis related genes and reduces apoptosis in porcine parthenotes developing in vitro[J]. Theriogenology,2005,63(4):1070-1080
[19]Torring N, Vinter-Jensen L, Pedersen SB, et al. Systemic administration of insulin-like growth factor Ⅰ (IGF-Ⅰ) causes growth of the rat prostate [J]. Urol,1997,158(1): 222-227
[20]Holly JM, Gunnell DJ, Davey SG. Growth hormone, IGF-Iand cancer. Less intervention to avoid cancer? More intervention to prevent cancer[J]. Endocrinol,1999,162(3) :321-30
[21]Chan JM, StampferMJ, Giovannucci E, et al. Plasma insulin-like growth factor-Ⅰ and prostate cancer risk:a prospective study[J]. Science,1998,279(53):563-566
[22]李欣,王禾,张盈涛ET-1、ETAR、IGF-Ⅰ R在正常前列腺和良性前列腺增生中的表达及意义[J].中华泌尿外科杂志,2003,24(7)：441
[23]毛庆波,张庆伟,刘琥.IGF-ⅠR在前列腺腺癌和前列腺增生组织中的分布和表达[J].济宁医学院学报,2002,25(2)：6-8
[24]Prayer-Galetti T, Rossi GP, Belloni AS. Gene expression and autographic localization of endothelin-1 and its receptors A and B in the different zones of the normal human prostate[J]. J Urol,1997,157:2334-2339
[25]Peehl DM, Cohen P, Rosenfeld RG. ReviewThe insulin-like growth factor system in the prostate[J]. World J Urol,1995,13(5):306-11
[26]Grant ES, Ross MB, Ballard S,et al.The insulin-like growth factor type I receptor stimulates growth and suppresses apoptosis in prostatic stromal cells[J]. J Clin Endocrinol Metab,1998,83(9):3252-3257
[27]KroemerG, Petit P, Zalnzami N, et al.The biochemistry of Progralnmed cell death[J]. FASEB J,1995,9:1277-1287
[28]Nagata S, Golstein P. The Fas death factor[M], Science,1995,267:1449-1456
[29]Enarlm, Hug H,Nagata S.Involvem ent of an ICE-ltke protease in Fas-mediated apoptosis[M].Nature,1995,375:78-81
[30]Seino K, Kayagai N, Fukao K, et al. Rejection of Fas ligand. expressing grafts [J]. Tans Proc,1997,29:1092-1093
[31]谢庆祥,汪鸿,缪友仁等.细胞凋亡相关基因bc1-2和bax在前列腺增生组织中表达的意义[J].中华泌尿外科杂志,1998,19(1)：98-100
[32]魏红山,李定国.细胞凋亡的信号转导机制与调节[J].国外医学分子生物学分册,2000,22(1)：27-31
[33]暨明,韦超凡.细胞凋亡启动与执行分子极其作用机制的研究进展[J].国外医学·生理、病理科学与临床分册,2001,21(2)：92-94
[34]Lee J, Richburg JH, Younkin SC et al.The Fas system is a key reguIator of germ cell apoptosis in the testis[J]. Endocrinology,1997,138(5):2081-2088.
[35]Kawakami A, Eguehi K. Involvement of apoptotic cell death in autoimmune diseases [J]. MedElectron Mierose,2002,35(1):1-8.
[36]Philchenkov AA. CasPases as regulators of apoptosis and other cell functions [J]. Bioehemistry(Mose),2003,68(4):365-376.
[37]郑佳,刘复强Fas/Fasl及其临床意义[J].首都医科大学报,2004,25(3)：411-414
[38]Ligand F. A Death factor and its receptor[J]. Adv Immunol,1994,57:129-144
[39]杨金瑞,黄循.前列腺疾病细胞凋亡及Bcl-2/Bax, Fas/Fasl调控研究[J].国外医学·泌尿系统分册,2000,20(4)：149
[40]谢庆祥,汪鸿.前列腺组织中细胞凋亡调控基因的表达[J].临床泌尿外科杂志,2000,15(7)：320-321
[41]曹继刚,周安方,舒劲松,等.仙甲汤对实验性前列腺增生大鼠前列腺组织FAS蛋白表达的影响[J].现代中西医结合杂志,2008,17(6)：823824
[42]段登志,于玲,张鸿青,等.前列回春对实验性大鼠前列腺组织Fas表达及细胞凋亡的影响[J].中国中药杂志,2003,(28)9：866-869
[43]Sasaki Y, Ahlned H. Takeuehi T, et al. Immunohistoehemical study of Fas. Fas ligand and inter leukin-1 converting enzyme expression in human Prostatic cancer [J].Br J Urol,1998,81:852-855
[44]EmiInui, AtushiQchiai, YoshiNaya, et al. Comparative morphometric study of bladder detrusor between patients with benign prostatic hyperplasia and controls [J].J Urol,1999,161(3):827-830
[45]黄旭元,易彬,陈斌,等.BPH患者膀肤逼尿肌细胞凋亡及Fas、Fasl表达的研究[J].中国男科学杂志,2005,19(6)：18-20
[1]Aggarwal S, Thareja S, Verma A, Bhardwaj TR, Kumar M. An overview on 5alpha-reductase inhibitors[J]. Steroids,2010,75(2)：109-153
[2]Suzuki K, Ito K, Ichinose Y, Kurokawa K, et al. Endocrine environment of benign prostatic hyperplasia:prostate size and volume are correlated with serum estrogen concentration[J]. Scand J Urol Nephrol,1995,29(1):65-68.
[3]张玉海,邵强.前列腺外科[M].北京：人民卫生出版社,2001,104-108
[4]张熙,贺菊乔,刘丽芳.前列散瘀胶囊治疗前列腺良性增生症的实验研究[J].湖南中医药导报,2004,10(1)：49-50.
[5]段登志,于玲,陈黎明.前列回春胶囊对实验性大鼠前列腺组织T、DHT含量的影响[J].新中医,2003,35(11)：75-76.
[6]曾宪彪,韦宝伟,李茂.前列通软胶囊对实验性大鼠前列腺增生和前列腺炎的影响术[J].中国现代医药,2007,9(10)：12-13.
[7]周建衡,洪振丰,林久茂.前列宁颗粒对大鼠前列腺增生的影响[J].福建中医学院学报,2008,18(5)：45-47
[8]张亚大,卢子杰,张平,等.益肾逐瘀汤治疗良性前列腺增生症100例疗效观察及对性激素的影响[J].新中医,2003,35(9)：14-15
[9]管家齐,宋捷民,陈海委,等.桂枝茯苓丸与桂枝水煎剂对前列腺增生小鼠影响的实验研究[J].中国中医药科技,2008,15(4)：259-260
[10]姚良权,李顺民,郭跃华,等.补骨脂素对大鼠前列腺增生治疗作用及对前列腺细胞雌雄激素受体的影响[J].北京中医药大学学报,2005,12(4)：8-10
[11]袁庆东,肖向茜,梁承.电针用于治疗大鼠实验性前列腺增生症的机制研究[J].中国康复医学杂志,2008,23(6)：532-534
[12]Kojima Y, Hayase M, Imura M, etal. The role of alphal-adrenoceptor subtypes in benign prostatic hyperplasia-from bed to bench[J]. Hinyokika Kiyo,2008,54(6):4 57-462
[13]Andersson KE. Alpha-adrenoceptors and benign prostatic hyperplasia:basic principles for treatment with alpha-adrenoceptor antagonists[J]. World J Urol, 2002,19(6):390-396
[14]郭应禄,胡礼泉.男科学[J].北京：人民卫生出版社,2005,1494
[15]张蜀武,常德贵,王久源,等.通关胶囊对离体人增生前列腺α1-AR的拮抗作用[J].中华男科学,2001,7(2)：136-138,140
[16]慈健,刘树民,宫大鑫,等.前列安栓对慢性前列腺炎和良性前列腺增生症患者尿流率的影响[J].中国男科学杂志,2003,17(2)：129-130
[17]席建元,贺菊乔,张熙,等.前列散瘀胶囊治疗良性前列腺增生的临床观察[J].中华男科学杂志,2005,11(1)：68-69,75
[18]许国振,崔金涛.决闭胶囊与保列治抗实验性前列腺增生作用的比较研究[J].中国中医药科技,2003,10(1)：9-10
[19]刘巧格,贾晓明,王生茂,等.尿通胶囊治疗老年前列腺增生症临床及实验研究[J].河北中医,2002,24(6)：403-407
[20]Soulitzis N, Karyotis I, Delakas D, et alExpression analysis of peptide growth factors VEGF, FGF2, TGFB1, EGF and IGF1 in prostate cancer and benign prostatic hyperplasia[J].Int J Oncol,2006,29(2):305-314
[21]De Bellis A, Ghiandi P, Comerci A, et al. Epidermal growth factor, epidermal growth factor receptor, and transforming growth factor-alpha in human hyperplastic prostate tissue:expression and cellular localization[J]. J Clin Endocrinol Metab, 1996,81(11)：4148-4154
[22]席建元,贺菊乔,周亮.前列散瘀胶囊对实验大鼠血清NO, bFGF影响的实验研究[J].新中医,2006,38(8)：89-90
[23]周亮,袁轶峰,贺菊乔.前列散瘀胶囊对实验性大鼠前列腺增生组织中碱性成纤维细胞表达的干预[J].中医药导报,2006,12(5)：65-66
[24]张凯,杨新宇,张军,等.泽桂癃爽胶囊治疗良性前列腺增生疗效和作用机理的初步研究[J].中华泌尿外科杂志,2003,24(6)：388-390.
[25]鲁会侠,张晓红,岳媛.前列舒通胶囊对实验性前列腺增生的作用[J].中国中西医结合外科杂志,2007,13(2)：155-158
[26]李翠英,周亮,贺菊乔.前癃通胶囊对体外培养基质细胞TGF-β1表达干预作用的研究[J].中国中医药科技,2005,12(2)：75-76
[27]蔡文清,黎玮,张勇.中药方剂Ⅰ号对小鼠前列腺细胞碱性成纤维细胞生长因子以及转化 生长因子-β1表达的影响[J].中华实验外科杂志,2007,24(7)：867-868
[28]贾金铭,马卫国,焦拥政.癃必消胶囊对体外培养的人前列腺增生间质细胞作用机制的实验研究[J].中国中西医结合杂志,2009,29(1)：55-58
[29]段登志,张鸿青,于玲.前列回春对实验性大鼠前列腺组织血.管内皮生长因子表达的影响[J].中华男科学,2004,10(2)：152-154
[30]Wang L, Yang JR, Yang LY, et al. Expression of Ki-67, Bcl-2, Bax and caspase-3 in benign prostatic hyperplasia combined with prostatitis and their significances[J]. Zhongnan Daxue Xuebao Yixueban,2008,33(3):222-226
[31]Iacopino F, Angelucci C, Lama G, et al. Apoptosis-related gene expression in benign prostatic hyperplasia and prostate carcinoma[J]. Anticancer Res,2006, 26 (3A):1849-1854
[32]Angelucci C,Iacopino F, Lama G, et al.Reverse transcriptase-PCR analysis of apoptosis-regulating gene expression in human benign prostatic hyperplasia[J]. Anticancer Res,2005,25(6B):3937-3941
[33]席建元,贺菊乔,周亮.前列散瘀胶囊对实验大鼠前列腺基底细胞凋亡的影响[J].江苏中医药,2005,26(10)：66-68
[34]黄源鹏,杜建,洪振丰.康泉方对大鼠前列腺组织凋亡调控基因bax、bcl-2 mRNA表达的影响[J].中国中西医结合杂志,2007,27(8)：711-712
[35]杨金瑞,黄循.前列腺疾病细胞凋亡及Bcl-2/Bax, Fas/Fasl调控研究[J].国外医学·泌尿系统分册,2000,20(4)：149
[36]段登志,于玲,张鸿青,等.前列回春对实验性大鼠前列腺组织Fas表达及细胞凋亡的影响[J].中国中药杂志,2003,(28)9：866-869
[37]曹继刚,周安方,舒劲松,等.仙甲汤对实验性前列腺增生大鼠前列腺组织FAS蛋白表达的影响[J].现代中西医结合杂志,2008,17(6)：823-824
[38]陈通文,邓春华,刘建中,等.前列通瘀提取液对前列腺平滑肌细胞增殖与凋亡的作用[J].中华医学研究杂志,2005,5(7)：626-627
[39]杨胜兰,曹继刚,周安方.仙甲汤对实验性前列腺增生大鼠前列腺组织细胞核增殖抗原表达的影响[J].华中科技大学学报(医学版),2006,35(3)：413,415
[40]Gradini R, Realacci M, Ginepri A, et al. Nitric oxide synthases in normal and benign hyperplastic human prostate:immunohistochemistry and molecular biology[J]. J Pathol,1999,189(2):224-229
[41]Bloch W, Klotz T, Loch C, et al. Distribution of nitric oxide synthase implies a regulation of circulation, smooth muscle tone, and secretory function in the human prostate by nitric oxide[J]. Prostate,1997,33(1):1-8
[42]贾金铭,马春涛,王勒渝,等.消癃通闭对前列腺平滑肌中NOS神经的影响[J].现代泌尿外科杂志,2001,6(2)：12-15
[43]候士良,许伏新.三妙胶囊治疗前列腺增生药理研究[J].中国中药杂志,2000,25(2)：110-114
[44]马卫国,贾金铭.中西医结合诊疗良性前列腺增生症的思路[J].中国男科学杂志,2009,23(4)：1-2
[2]顾方六.现代前列腺病学[M].北京：人民军医出版社,2002,53
[3]Kaplan SA,McConnell JD, Roehrborn CG, et al. Medical Therapy of Prostatic Symptoms (MTOPS) Research Group. Combination therapy wwith doxazosin and finasteride for benign prostatic hyperplasia in patients with lower urinary tract symptoms and a baseline total prostate volume of 25ml or greater[J]. J Urol,2006,175:217-220
[4]Djavan B, Chapple C, Milani S, et al. State of the art on the efficacy and tolerability of alphal- adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia[J]. Urology,2004,64: 1081-1088
[5]贺菊乔.前列腺疾病中西医诊治之我见[J].中医药导报,2005,11(1)：22-24
[1]杨勇译,郭应禄校.第五届国际良性前列腺增生咨询委员会国际科学委员会推荐意见：老年男性下尿路症状的评估和治疗[J].中华泌尿外科杂志,2001,22(9)：564-570
[2]郑筱萸.中药新药临床研究指导原则(试行)[M].北京：中国医药科技出版社,2002,305
[3]段登志,张鸿青,于玲.前列回春对实验性大鼠前列腺组织血管内皮生长因子表达的影响[J].中华男科学,2004,10(2)：152-154
[4]黄源鹏,杜建,洪振丰.康泉方对大鼠前列腺组织凋亡调控基因bax、bc1-2 mRNA表达的影响[J].中国中西医结合杂志,2007,27(8)：711-712
[5]陈奇.中药药理实验方法学[M].北京：人民卫生出版社,2006,93-95
[6]中医病证诊断疗效标准[S].南京：南京大学出版社,1994,144
[7]马卫国.癃必消胶囊对前列腺增生间质细胞作用机理的实验研究与临床观察[D].博士学位论文,2003,90
[8]张智琳.从肺论治男科病初探[J].中国医药学报,2004,8(19)：487-488
[9]夏忠诚,余国英,徐剑刚.温宣通淋方治疗良性前列腺增生30例[J].中国临床医生,2008,36(7)：44-45
[10]陈金荣,候思理.前列腺增生从气血痰水论治探讨[J].中国医药学报,1999,5(14)：48-50
[11]王振新.自拟三甲汤治疗急性尿缩留21例[J].四川中医,2001,19(8)：49
[12]赵建业,戴福寿.以活血法治疗前列腺增生症经验[J].福建中医药,2004,35(2)：21-22
[13]韩伍龙.从痰瘀论治前列腺增生症30例[J].四川中医,2001,19(10)：46
[14]叶科贵.辩证论治前列腺增生症67例[J].河南中医,2006,26(7)：43-44
[15]刘亮.补气化瘀法治疗前列腺增生继发尿潴留[J].中国中医急症,2005,4(1)：378
[16]朱源北.补肾活血法治疗老年癃闭的体会[J].黑龙江中医药,2006,7(4)：28
[17]李富玉,许彦来,张少林.自制路通颗粒治疗老年前列腺增生症63例[J].实用医药杂志,2007,1(24)：64-65
[18]资桂平.益癃汤治疗前列腺增生症例临床观察[J].湖南中医药报,2003,9(6)：37-38
[19]黄源鹏,吴锦发.中医络病理论与良性前列腺增生关系探析[J].中华中医药杂志,2006,1(21)：45-46
[20]张亚大,卢子杰,张平,等.益肾逐瘀汤治疗良性前列腺增生30例疗效观察[J].南京中医药大学学报(自然科学版),2001,17(4)：216-217
[21]王晓春.补肾化瘀散结汤治疗前列腺增生76例[J].河北中医,2007,29(1)：50
[22]马晓勇,陈丽君.温肾化瘀法治疗前列腺增生48例[J].陕西中医,2000,21(10)：442
[23]王劲松.前列腺增生症论治五法[J].四川中医,2000,12(18)：11-12
[24]郭明福.开利散结汤治疗前列腺增生110例[J].江苏中医药,2003,24(3)：34
[25]谢昌仁.名老中医治疗良性前列腺增生经验荟萃[J].中国临床医生,2006,4(34)：57-59
[26]蓝毕生.通补奇经方治疗良胜前列腺增生症32例[J].吉林中医药,2002,22(3)：191
[27]胡臻.升阳通络汤治疗前列腺增生症20例[J].中国中医药信息杂志,2002,9(9)：53
[28]何红兵.从瘀辩证分型治疗老龄前列腺增生症72例[J].安徽中医临床杂志,2001,13(3)：181
[29]贺菊乔.前列腺疾病中西医诊治之我见[J].中医药导报,2005,11(1)：22-24
[30]郭应禄,胡礼泉.男科学[M].北京：人民卫生出版社,2005,1495-1496
[31]willson JD. The pathogenesis of benign proztatl chyperplasia[J]. Am J cd 1980; 68:745
[32]Lu ML, Schneider MC, Zheng Y, et al. Caveolin-1 interacts with androgen receptor. A positive modulator of androgen receptor mediated transactivation[J]. J Dial Client,2001,276:13442-13451
[33]Steers WD.5 alpha-reductase activity in the prostate[J]:Urology,2001,58(6 Suppl 1):17-24
[34]Xia SJ,Xu CX, Tang XD,et al. Apoptosis and hormonal milieu in ductalsystem of normal prostate and benign prostatic hyperplasia[J]. Asian J An-drol,2001,3:131-134
[35]吴荃,肖向茜,刘树业,等.雌二醇通过调节上皮细胞系的旁分泌促进前列腺间质细胞 增殖和分化[J].中国病理生理杂志,2007,23(7)：1382-1387
[36]Michaud L B. Adjuvantuse of aromatase inhibitors in postmenopausal women with breast cancer[J]. Am J Health Systpharm,2005,62(3):266-273
[37]Monti S, Di SilverioF, IraciR, etal. Regional variations of insulin-like growth factor Ⅰ (IGF-Ⅰ), IGF-Ⅱ, and receptor type Ⅰ in benign prostatic hyperplasia tissue and their correlation with intraprostatic androgens[J]. Clin Endocrinol Metab, 2001,86(4):1700-1706
[38]Royuela M, de Miguel MP,Bethencourt FR, et al. Estrogen receptors alpha and beta in the normal, hyperplastic and careinamatous human protate[J]. J Endocrinol, 2001,168(3):447-454
[39]Salazar EL, Mercado E, Calzada L. Prostatic cancer/benign prostatic hypertrophy. Subcellular distribution of estradiol/androgen receptors[J]. Arch Androl,2005, 51 (2):135-139
[40]Smith P.Rhodes NP,Ke Y.Foster CS. Relationship between upregulated oestrogen receptors and expression of growth factors incultured, human, prostatic stromal cells exposed to estradiol or dihydrotestosterone[J]. Prostate Cancer Prostatic Dis,2004, 7(1):57-62
[41]Smith P.Rhodes NP, Ke Y.Foster CS. Upregulation of estrogen and androgen receptors modulate expression of FGF-2 and FGF-7 in human, cultured, prostatic stromal cells exposed to high concentrations of estradiol[J]. Prostate Cancer Prostatic Dis,2002,5(2):105-110
[42]Habermann H, Ray V,Habermann W, et al. Alterations in gap junction protein expression in human benign prostatic hyperplasia and prostate cancer[J].J Urol, 2002,167 (2Ptl):655-660
[43]叶烈夫,张元芳,方祖军,等.5 a-还原酶在良胜增生前列腺组织中的表达及意义[J].中华医学杂志,2003,83(15)：1296-1299
[44]Steers WD.5 alpha-reductase activity in the prostate [J]. Urology,2001,58(6):17-24
[45]Carballido, Rodriguez, Rodriguez Vallejo, et al. Benign prostatic hyperplasia and Evidence based medicine:itsapproach in clinical practice[J]. MedClin(Barc), 2000,114(SuPP12):96-104
[46]郭应禄,胡礼泉.男科学[M].北京：人民卫生出版社,2005,1496-1497
[47]Sciarra F, Toscano V. Role of estrogens in human prostatic hyperplasia[J]. Areh Androl,2000,44(3):213-220
[48]谢庆祥,汪鸿,林福地,等.生长调控因子异常与良性前列腺增生的关系[J].中华泌尿外科杂志,2001,22(9)：520-522
[49]Story MT, Hopp KA, Meier DA, et al. Influence of transforming growth factor β 1 and other growth factors on basic fibroblast growth factor level and proliferation of cultured human prostated-derived fibroblast[J]. The Prostate,1993,22(4):183
[50]Gleason PE, Jones JA, Regan JA, et al. Platelet derived growth factor, androgens and imf lammation:possible ecology factors in the development of prostatic hyperplasia[J]. J Urol,1993,149(12):1586
[51]Funa K, Nordgren H, Nilsson S, In expression of mRNA for Proseongenes in benign Prostatic hyprerplasia[J]. Scand J Urol Nephrol,1991,25(2):95
[52]那彦群,郭震华.实用泌尿外科学[M].北京：人民卫生出版社,2009,387-388
[53]Jacoba SC. Story MT, Sasse J, et al. Charaeterization of growth factors derived From the rat ventral prostate[J]. J Urol,1988,139(11):1106
[54]Story MT, Vingaton B, Baeten L, et al. Cultured human prostate-derived fibroblasta produce a factor that accumulate their growth with Proper f ies in distinguiehable from basic fibroblast growth factor[J]. Prostate,1989,15(7):355
[55]Sinowatz F, Schams D, Einspanier R, et al. Cellular localization of fibroblast growth factor 2(FGF-2) in beign prostatic hyperplasia[J]. Histopathol,2000,15: 475
[56]闫爰中,曾照锦,张治国,等.前列腺组织中EGF、bFGF的表达[J].临床泌尿外科杂志,2001,16(1)：27-29
[57]Dow JK, Vere White RW, Fibroblast growth factor2:its structure and property, paracrine function, tumor angiogenesis, and prostate-related mitogenic and oncogeniic functions[J]. urology,2000,55:800
[58]Morris GL, Dodd JG. Epidermat growth factormRNA levels in human prostate tumors And cell lines[J].J Urol,1990,143(3):127
[59]Gann PH, Klein KG, Chatterton RT, et al. Growth factors in expressed prostatic fluid from men with prostate cancer, BPH, and clinically normal prostates[J]. Prostate, 1999,40(41):248-55
[60]贾彬,蔡文清,黎玮,等.表皮生长因子对小鼠前列腺细胞增殖凋亡的影响[J].河北医科大学学报,2005,26(3)：204-205
[61]Grorge KI, Billie-Jo MK, James AM, et al. Differential immunoreactivity of epidermal growth factor receptor in benign,dysplastic and malignant prostatic tissues[J]. J Urol,1993,14(9):170-173
[62]Sherwood ER, Lee C. Epidermal growth factor-related peptides and the epidermal growth factor receptor in normal and malignantprostate[J]. World J Urol,1995,13 (5):290
[63]Ibrahim GK, MaeDonald JA, Ibrahim SN, et al. Differential immunoreactivity of Epidermal growth factor receptor in benign, clysplastic and malignant prostatic Tissues[J]. J Urot,1993,149(4):170
[64]SixtinaGL, Diez SG, Hi jazi A, et al. Inereased basal Cell prolifereroPhy and EGF receptor exceptor expression in benign hypertrophy compared to normal prostate [J].J Urol,1993,149(5):243
[65]Ftydrenberg M, Foo TM, Jones AS, et al. Benign prostatic hyplasia-video image analyais and its relationship to androgen and epidermal growth faetor recptorexpression [J].J Urol,1991,146(10):872
[66]贾彬,汤泓,黎玮,等.表皮生长因子对小鼠前列腺细胞雌雄激素受体表达的影响[J].南方医科大学学报,2006,26(10)：1473-1475
[67]韩丽华,孙佩杰,王和,等.表皮生长因子受体和雄激素受体在前列腺增生及其前列腺癌组织中的表达[J].中国临床康复,2005,9(18)：138-139
[68]Seiarra F, Monti S, Adamo MV, et al. Regional distribution of epidermal growth factor, testosterone and dihydrotestosterone in benign prostatie hyperplasia tissue[J]. Urol Res,1995,23:387-390
[69]Marti kainen P, Ky Prianou N, Isaaes JT, et al. Effect of transforming grow factor-Ion proliferation and death of rat prostatic cells[J]. Endoerinology,1990, 127(12):296-297
[70]Wilding G. Response of prostate cancer cells to peptide grow factors:transforming growth factor-beta[J]. Cancer Surv,1991,11(2):147
[71]Massague J. Effect of transforming growth factor in human prostate[J]. J Biol Chem,1990,265 (21):393
[72]PeehlDM, RG Sellers. Basic FGF, EGF, and PDGF Modify TGF-β1 induction of smooth muscle cell phenotype in human prostatic stromal cells[J]. Prostate,1998,35(2): 125-134
[73]Ilio KY, Park II, PinsMR, et al.Apoptotic activity of doxazosin on prostate stromain vitrois mediated through an autocrine expression of TGF-betal[J]. Prostate, 2001,48(3):131-135
[74]Zhou W, Park I, PinsM, et a.1 Dual regulation of proliferation and growth arrest in prostatic stromal cells by transforming growth factor-β1[J]. Endocrinology, 2003,144(10):4280-4284
[75]吴荃,肖向茜,刘树业.雌二醇通过调节上皮细胞系的旁分泌促进前列腺间质细胞增殖和分化[J].中国病理生理杂志,2007,23(7)：1382-1387
[76]Hsing AY, Kadomatsu K,Bonham MJ,et al. Regulation of apoptosis induced byTGF-β1 in nontumorigenic & tumorigenic rat prostatic epithelial cell lines[J]. Camcer res,1996,56:5146-5150
[77]Ilio KY, Sensibar JA, Lee C. Effect of TGF-β1, TGF-αand EGFon cell proliferation &cell death in rat vental prostaic epithelial cells in culture[J].J Adrol,1995,16: 482-490
[78]Peehl DM, Sellers RG. Basic FGF, EGF and PDGF modify TGF-β-induction of smooth m uscle cellphenotype in human prostatic stromal cells [J]. Prostate,1998,35 (2) :125-134
[79]牛远杰,张琚,马腾骧,等TGF-β1, bFGF对前列腺基质细胞增殖和分化的影响[J].中华泌尿外科杂志,1999,20(12)：749-752
[80]UntergasserG, Gander R, Lilg C, et al. Profiling molecular targets of TGF-betal in prostate fibroblast to myofibroblast transdifferentiation [J]. Mech Ageing Dev,2005,126(1):59-69
[81]Story MT, Hopp KA, Meier DA, et al. Influence of transforming growth factor β1 and other growth factors on basic fibroblast growth factor level and prolife ration of cultured human prostated-derived fibroblast[J]. The Prostate,1993, 22(4):183
[82]王建业,左涛,万奔.体外转化生长因子1与表皮生长因子对人前列腺上皮细胞增殖的作用调节[J].中老年医学杂志,2001,20(4)：255-256
[83]牛远杰,张琚,马腾骧,等TGF-β1/bFGF对前列腺基质细胞增殖和分化的影响[J].中华泌尿外科杂志,1999,20：749-752
[84]Kerr JFR, Wylie AH. Curri.e AR. Apoptosis:a basic biological phenomenon with wide-ranging implications in tissue kinetics[J]. Br J Caneer,1972,26:239-257
[85]杨金瑞,黄循,杨竹林.前列腺增生和前列腺癌组织细胞凋亡及bcl-2、bax基因表达的研究[J].中华泌尿外科杂志,2000,21(8)：485-487
[86]石建党,李江峰,杨洪波,等.良性前列腺增生组织中基质细胞的增殖和凋亡[J].中国病理生理杂志,2005,21(4)：817-819
[87]邓方明,顾方六,夏同礼,等.人良性前列腺增生细胞增殖和凋亡状态的研究[J].中华外科杂志,1996,34(10)：620-622
[88]邵强,马骏,张玉海,等.良性前列腺增生不同区带的细胞增殖和凋亡状态的研究[J].中华泌尿外科杂志,2001,22(3)：164-166
[89]杨金瑞,黄循.前列腺疾病细胞凋亡及Bcl-2/Bax, Fas/Fasl调控研究[J].国外医学·泌尿系统分册,2000,20(4)：149
[90]胡野,凌志强,单小云.细胞凋亡的分子医学[M].第1版.北京：军事科学出版社,2002,8(1)：3-9
[91]Royuela M, De Miguel MP. Bethencourt FR, et al. bcl-2 its reeeptors. And bcl-2 and bax genes in normal. Hyperplastic and carcinomatous humanprostates:Immunohi-stochemical comparative analysis[J].Growth Faetors,2000,18(2):135-146
[92]Hegarty Paul K, Watson R. William G, et al. Effeets of cyclic stretch on prostatic cells in culture[J]. J Urol,2002,168(5):2291-2295
[93]Badawi. Alaa F, liu yin yin. Eledden, Mazen B, et al. Age-assoeiated changes in the expression Pattem of cyclooxygenase-2 and related Apoptotic markers in the cancer susceptible region of rat prostate [J]. Carcinogenesis,2004,25(9):1681-1688
[94]Wang W. Bergh A. Damber JE. Chronic inflammation in benign prostate hyperplasia is associated with focal upregulation of cyclooxygenase-2[J]. bcl-2 and cell proliferation in the glandular epithelium[J]. Prostate,2004,61(1):60-72
[95]贾彬,蔡文清,黎伟,等.雌激素对前列腺增生症移行区细胞bcl-2、bax和C-myc基因表达的影响[J].中华实验外科杂志,2004,21(1)：77-78
[96]王小峰,叶海云,姜辉,等.雄激素对良性前列腺增生组织中bcl-2mRNA表达的影响[J].中华外科杂志,2000,38(3)：198-200
[97]Cardillo M, Berchem G, Tarkington MA, et al. Resistance to apoptosis and up regulation of bcl-2 in benign prostatic hyperplasia after androgen deprivation[J]. J urol,1997,158:212-216
[98]Gandour-Edwards R. Mack PC. Devere-White RW, et al. Abnormalities ofApoptotic and cell cycle regulatory Proteins in distinct histopathologic components of benign prostatic hyperplasia[J]. Prostate Caneer Prostatie Dis,2004,17(10):1038-1041
[99]Mare Colombel, CarlA. 01ssom, et al. Hormone-regulated apoptosis results from reentry of differentiated prosate[J]. Cancer Res,1992,52:4313-4319
[100]Richard R, Berges. Yuzo Furuya, et al. cell proliferation DNA repair. And P53 function are not required for programmed death of prostatic glandular cells induced by androgen ablation[J]. Proc Natl Acad Sci USA,1993,90:8910-8914
[101]Shin S C B, Cho Y S. An antiapoptotic protein human survivin is a direct inhibtior of caspase-3 and-7[J].J Biochemistry,2001,40:1117-1123
[102]0'Neill A J, Boran S A,O' Keane C, et al. Caspase 3 expression in benign prostatic hyperplasia and prostate carcinoma[J]. Prostate,2001,47(3):183
[103]Soha J H, Kim D H, Choi N G, et al. Caspase-3/CPP 32 immunoreactivity and its correlation with frequency of apoptotic bodies in human prostatic carcinomos and benign nodular hyperplasias[J]. Histopathology,2003,37(6):555
[104]Shariat S F, Ashfaq R, Roehrborn C G, et al. Expression of survivin and apoptotic biomarkers in benign prostatic hyperplasia[J]. J Urol,2005,174:2046-2050
[105]邓春华,丘少鹏,陈辉熔,等Caspase-3在前列腺组织中的表达和意义[J].中华男科学杂志,2003,17(4)：224-228
[106]魏强.良性前列腺增生症的治疗[J].临床药物治疗杂志,2007,5(2)：18-21
[107]Kyprianou N, Litvak JP,Borkowski A, et al. Induction of prostate apoptosis by doxazosin in benign prostatic hyperplasia. J Urol,1998,159:1810-1815
[108]刘孝东,杨宇如,卢一平,等.非那雄胺减少TURP术中出血的机理研究[J].中华泌尿外科杂志,2003,24(10)：694-697
[109]RUVskewitz R, Girman CJ, Fowler J, et al. Effect of finasteride on bother and other health related quality of life aspects associated with benign prostatic hyperplasia[J]. Urology,1999,54:670-678
[110]Lepor H, Williford W0, Barry MJ, et al. The efficacy of terazosin, finasteride or both in benign prostatic hyperplasia. vete-rans affairs cooperative studies benign prostatic hyperplasia study group[J]. Nengl J Med,1996,335:533-539
[111]Kaplan SA.Long-term sustained improvement in sym ptoms of benign prostatic hyperplasia with the dual 5alpha-reductase inhibitor dutasteride:results of 4-year studies[J].J Urol,2006,175(6):2211-2212
[112]Mc connell JD, Ruvskewitz R, Walsh P, et al. the effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. finasteride long-term efficacy and safety study group[J]. Nengl j Med,1998,338:557-563
[113]Kaplan SA. Medical therapy in the management of bph. Progression versus symptoms [A]. Office education of 94th annual meeting aua,1999,44-45
[114]Hudson PB, Boake R, Trachtenberg J, et al. Efficiency of finasteride is maintained in patients with bph treated for 5 years[J]. Urology,1999,53:690-695
[115]陈光,臧文臣.黄芪多糖对动物肿瘤细胞凋亡影响的研究[J].中医药学报,2002(4)：30
[116]薛红漫,孟哲,郭海霞,等.黄芪浸膏粉诱导Jurkat clone E621细胞凋[J].中国实验诊断学,2005,8(4)：9
[117]李帆,梁敬钰.王不留行的研究进展[J].海峡药学,2007,19(3)：1-4
[118]劳爱娜,桑圣民.常用中药基础研究(第五章)[M].北京：高等教育出版社,2002,80-112
[119]吴金玉,黄雪霞,史伟,等.田七注射液对肾病综合征患者血脂及血液流病学的影响[J].广西医学,2005,27(12)：194-196
[120]张喜平,齐丽丽,刘达人.三七及其有效成分的药理作用研究现状[J].医学研究杂志,2007,36(4)：96-98
[121]谢新生,张秀丽.穿山甲煎液诱导HL-60细胞凋亡的研究[J].浙江中西医结合杂志,2001,11(8)：477-479
[122]刘京生,苗智慧,董力,等.水蛭抗肿瘤作用的实验研究[J].时珍国医国药,2001,12(10)：884-885.
[123]袁淑兰,王修杰.丹参酮抗肿瘤作用及其机理的研究[J].癌症,2003,22(12)：1363-1366.
[124]贾金铭.中国中西医结合男科学[M].北京：中国医药科技出版社,2005,304
[125]祁公任,陈涛.前列腺增生症中医临床疗效评价标准的探讨[J].江苏中医,1999,20(8)：7-8
[126]贾金铭.中国中西医结合男科学[M].北京：中国医药科技出版社,2005,302
[127]张岐山,郭应禄.泌尿系超声诊断学[M].北京：科学技术文献出版社,2001,292-293
[128]李诺,阮园,张慧娟.超声测定良性前列腺增生患者残余尿量的临床意义[J].徐州医学院学报,2009,29(8)：544-545
[129]吴阶平.吴阶平泌尿外科学[M].济南：山东科学技术出版社,2004,1134-1158
[130]武治津,张鹏,张居忠,等.良性前列腺增生患者膀胱出口梗阻及逼尿肌强度对剩余尿的影响[J].中华泌尿外科杂志,2002,23(9)：548-549
[131]周立群,陈为民,那彦群,等.良性前列腺增生与前列腺癌患者血清PSA水平与游离PSA比值的比较[J].中华泌尿外科杂志,2002,23(6)：354.
[132]Schulman CC. Lower urinary tract symptoms/benign prostatic hyperplasia: minimizing morbidity caused by treatment[J]. Urology,2003,62(3 Suppll):24-33
[133]Boyle P, Robertson C, Mazzetta C, et al. The association between lower urinary tract symptoms and erectile dysfunction in four centres:the UrEpik study[J]. BJU Int,2003,92:719-725
[134]McVary KT. Sexual dysfunction in men with lower urinary tract symptoms and benign hyperplasia:an meringlink[J]. BJU int,2003,91:770-771
[135]Pahlman S, Meyerson G, Lindgren E, et al. Insulin-like growth factor-I shifts from premoting cell division to potentiating maturation during neurona differentiation [J].Pnas,1991,88:99-104
[136]EI-Badry 0, Romanus J, Helman L, et al. Automous growth of a human neuroblastoma cell line is mediated by insulin-like growth factor-Ⅱ [J]. J Clin Invest,1989,84:829
[137]Kleinberg DL, R uan W, Yee D, et al. Insulin-like growth factor (IGF)-I controls prostate fibromuscular development:IGF-I inhibition prevents both fibromuscular and glandular development in eugonadal mice[J]. Endocrinology,2007,148(3):1080-1088
[138]Soulitzis N, Karyotis I, Delakas D, et al. Expression analysis of peptide growth factors VEGF, FGF2, TGFB1, EGF and IGF1 in prostate cancer and benign prostatic hyperplasia[J]. Int J Oncol,2006,29(2):305-314
[139]姜辉,朱积川,许清泉.雌、雄激素对前列腺中IGF-I基因表达的影响[J].中华泌尿 外科杂志,2000,21(4)：227-228
[140]Cui X S ong Y Jjun J H, et al. Insulin-like growth factor-I alters apoptosis related genes and reduces apoptosis in porcine parthenotes developing in vitro[J]. Theriogenology,2005,63(4):1070-1080
[141]Monti S, Di SilverioF, IraciR, etal. Regional variations of insulin-like growth factor Ⅰ (IGF-Ⅰ), IGF-Ⅱ, and receptor type Ⅰ in benign prostatic hyperplasia tissue and their correlation with intraprostatic androgens[J]. Clin Endocrinol Metab, 2001,86(4):1700-1706
[142]姜辉,朱积川,王晓峰,等.胰岛素样生长因子Ⅰ、Ⅱ与其受体mRNA在前列腺增生组织中表达[J].中华泌尿外科杂志,1997,18(9)：564-566
[143]姜辉,叶海云,许清泉,等.Bcl-2和IGF-Ⅰ mRNA在正常和增生前列腺组织中表达及意义[J].中国男科学杂志,2001,15(1)：20-22
[144]Grant ES, Ross MB, Ballard S, et al. The insulin-like growth factor type Ⅰ receptor stimulates growth and suppresses apoptosis in prostatic stromal cells[J]. J Clin Endocrinol Metab,1998,83(9):3252-3257
[145]Prayer-Galetti T, Rossi GP, Belloni AS. Gene expression and autographic localization of endothelin-1 and its receptors A and B in the different zones of the normal human prostate[J]. J Urol,1997,157:2334-2339
[146]Torring N, Vinter-Jensen L, Pedersen SB, et al. Systemic administration of insulin-like growth factor I (IGF-I) causes growth of the rat prostate[J], Urol, 1997,158(1):222-227
[147]Nagata S, Golstein P. The Fas death factor[J]. Seience,1995:267(5203):1449-1156
[148]郑佳,刘复强Fas/Fas1及其临床意义[J].首都医科大学报,2004,25(3)：411-414
[149]魏红山,李定国.细胞凋亡的信号转导机制与调节[J].国外医学分子生物学分册,2000,22(1)：27-31
[150]暨明,韦超凡.细胞凋亡启动与执行分子极其作用机制的研究进展[J].国外医学、生理、病理科学与临床分册,2001,21(2)：92-94
[151]Lee J, Richburg JH, Younkin SC etal. The Fas system is a key regulator of germ cell apoptosis in the testis. [J].Endocrinology.1997,138(5):2081-2088
[152]Kawakami A, Eguehi K. Involvement of apoptotic cell death in autoimmune diseases[J]. Med Electron Mierose,2002,35(1):1-8
[153]Philchenkov AA. CasPases as regulators of apoptosis and other cell functions [J]. Bioehemistry(Mose),2003,68 (4):365-376
[154]谢庆祥,汪鸿.前列腺组织中细胞凋亡调控基因的表达[J].临床泌尿外科杂志,2000,15(7)：320-321
[155]曹继刚,周安方,舒劲松,等.仙甲汤对实验性前列腺增生大鼠前列腺组织FAS蛋白表达的影响[J].现代中西医结合杂志,2008,17(6)：823-824
[156]段登志,于玲,张鸿青,等.前列回春对实验性大鼠前列腺组织Fas表达及细胞凋亡的影响[J].中国中药杂志,2003,(28)9：866-869
[157]Sasaki Y, Ahlned H. Takeuehi T, et al. Immunohistoehemical study of Fas. Fas ligand and inter leukin-1 converting enzyme expression in human prostatic cancer[J].Br J Urol,1998,81:852-855
[158]黄旭元,易彬,陈斌,等.BPH患者膀胱逼尿肌细胞凋亡及Fas、Fas1表达的研究[J].中国男科学杂志,2005,19(6)：18-20
[159]吴建辉,孙祖越,朱焰.去势Beagle犬前列腺增生模型的建立[J].中华男科学杂志,2003,9(6)：425-428
[160]陈晖,刘修恒,金化民.雌雄激素联用制作犬前列腺增生动物模型[J].临床泌尿外科杂志,2005,20(1)：44-46
[161]尚平,许宏等.性激素缓释硅胶囊对去势狗的激素替代作用[J].中国男科学杂志, 2000,14(2)：86-87
[162]Steiner MS, Couch RC, Stauffer D, et al. The chimpanzee as a model of human BPH[J]. J Urol,1999,162:1454-1461
[163]Tutrone RF, Ball RA, Ornitz DM, et al. Benign prostatic hyperplasia in a tranagenic mouse, a new hormonally hyperplasia sensitive inverstigatory model [J]. Urol,1993,149 (9):533
[164]张学军.bcl-2基因在良性前列腺增生中的作用[J].中华泌尿外科杂志,1997,18(2)：97-99
[165]余帆,宋波.尿生殖窦诱导的鼠前列腺增生模型制备[J].第三军医大学学报,1999,2(2)：131-132
[166]安军明.针刺对丙酸睾丸素所致小白鼠前列腺增生症疗效的实验观察[J].中国针灸,1998,18(6)：357
[167]孙伟桂,叶章群,米振国,等.改良简化的小鼠BPH模型及其特点[J].中国男科学杂志,2008,22(1)：24-27
[168]司瑜,王卫华,张金华,等.日龄对小鼠前列腺增生模型的影响[J].中国民康医学,2010,22(18)：2305,2332
[169]董佳晨,贾金铭,马卫国.癃闭消(消癃通闭)胶囊对BPH大鼠模型内皮素-1表达的影响[J].中国男科学杂志,2009,33(4)：35-38
[170]苗明三.对中医药研究中动物模型应用的探讨[J].河南中医药学刊,2000,15(1)：2-4
[171]叶建红.浅议中医证候动物模型制作[J].广西中医学院学报,2001,4(2)：79
[172]郭书文,孟庆刚,王硕仁.病证结合模型的研究思路[J].中医药学报,2001,29(1)：2-3
[173]冯毅翀,吴薇.对病证结合动物模型研制的一点看法和设想[J].现代中西医结合杂志,2005,14(8)：1112-1113
[174]张红宇,高菊珍,张晓华.补阳还五汤对气虚血瘀证大鼠血液流变学的影响[J].云南中医学院学报,2003,3(3)：10-11
[175]庞树玲,高金亮.中年大鼠气虚血瘀证的模拟及其机理探讨[J].天津中医学院学报,1997,16(3)：28-30
[1]Rosen C J, Pollak M. Circulating IGF-Ⅰ:New perspectives for a new century[J]. TEM,1999,10:136-141
[2]Frank SJ. Growth hormone, insulin-like growth factor Ⅰ, and growth:local knowledge[J]. Endocrinology,2007,148(4):1486-1488
[3]Klover P, Hennighausen L. Postnatal body growth is dependent on the transcription factors signal transducers andactivators of transcription 5a/b in muscle:a role for auto-crine/paracrine insulin-like growth factor-Ⅰ[J]. Endocrinology,2007,148 (4):1489-1497
[4]Pahlman S, Meyerson G,Lindgren E, et al. Insulin-like growth factor-Ⅰ shifts from premoting cell division to potentiating maturation during neurona differentiation [J]. Pnas,1991,88:99-104
[5]EI-Badry O, Romanus J, Helman L, et al. Automous growth of a human neuroblastoma cell line is mediated by insulin-like growth factor-Ⅱ [J]. J Clin Invest,1989,84:829
[6]Martin D, Feldman E. Regulation of insulin-like growth factor-Ⅱexpression andits role in autocrine growth of human neuroblastoma cells[J].J Cell Physiol,1993,15 5:290
[7]Barres B, Hart I, Co lesM,et al.Cell death and control of cell survival in the oligodendrocyte lineage[J]. Cell,1992,70:31
[8]Xu Zhe, Liu Fu-Kun, Qi Xiao-Ping, et al. The expression between insulin-like growth factor-Hand prognosis of colorectal patients[J]. Zhong Hua Wai Ke Zha Zhi,1999, 37(12):718-720
[9]Peters MG, Farias E, Colombo L, et al. Inhibition of invasion and metastasis by glypocan-3 in a syngeneic breast cancer model[J].B reast Cancer Res Treat,2003, 80(2):221-232
[10]Twigg S M, Baxter R C. IGF binding protein 5 forms an alternative ternary complex with IGFs and the acid lable subunit [J]. J Biol Chem,1998,273:6074-6079.
[11]Sarm a AV, Jaffe CA, Schottenf Eld D, et al. Insulin-like growth factor-1, insulin-like growth factor binding protein-3, and body mass index:clinical correlates of prostate volume among Black men [J]. Urology,2002,59(3):362-367
[12]Monti S, Di SilverioF, IraciR, et al. Regional variations of insulin-like growth factor Ⅰ (IGF-Ⅰ), IGF-Ⅱ, and receptor type Ⅰ in benign prostatic hyperplasia tissue and their correlation with intraprostatic androgens[J]. Clin Endocrinol Metab 2001,86 (4):1700-1706
[13]姜辉,朱积川,王晓峰,等.胰岛素样生长因子Ⅰ、Ⅱ与其受体mRNA在前列腺增生组织中表达[J].中华泌尿外科杂志,1997,18(9)：564-566
[14]姜辉,叶海云,许清泉,等.Bcl-2和IGF-Ⅰ mRNA在正常和增生前列腺组织中表达及意义[J].中国男利学杂志,2001,15(1)：20-22
[15]Kleinberg DL, R uan W, Yee D, et al. Insulin-like growth factor (IGF)-Ⅰ controls prostate fibromuscular development:IGF-Ⅰ inhibition prevents both fibromuscular and glandular development in eugonadal mice[J]. Endocrinology.2007,148(3):1080-1088
[16]Soulitzis N, Karyotis Ⅰ, Delakas D, et al. Expression analysis of peptide growth factors VEGF, FGF2, TGFB1, EGF and IGF1 in prostate cancer and benign prostatic hyperplasia[J]. Int J Oncol,2006,29(2):305-314
[17]姜辉,朱积川,许清泉.雌、雄激素对前列腺中IGF-Ⅰ基因表达的影响[J].中华泌尿外科杂志,2000,21(4)：227-228
[18]Cui X S ong Y.Jjun J H, et al. Insulin-like growth factor-Ⅰ alters apoptosis related genes and reduces apoptosis in porcine parthenotes developing in vitro[J]. Theriogenology,2005,63(4):1070-1080
[19]Torring N, Vinter-Jensen L, Pedersen SB, et al. Systemic administration of insulin-like growth factor Ⅰ (IGF-Ⅰ) causes growth of the rat prostate [J]. Urol,1997,158(1): 222-227
[20]Holly JM, Gunnell DJ, Davey SG. Growth hormone, IGF-Iand cancer. Less intervention to avoid cancer? More intervention to prevent cancer[J]. Endocrinol,1999,162(3) :321-30
[21]Chan JM, StampferMJ, Giovannucci E, et al. Plasma insulin-like growth factor-Ⅰ and prostate cancer risk:a prospective study[J]. Science,1998,279(53):563-566
[22]李欣,王禾,张盈涛ET-1、ETAR、IGF-Ⅰ R在正常前列腺和良性前列腺增生中的表达及意义[J].中华泌尿外科杂志,2003,24(7)：441
[23]毛庆波,张庆伟,刘琥.IGF-ⅠR在前列腺腺癌和前列腺增生组织中的分布和表达[J].济宁医学院学报,2002,25(2)：6-8
[24]Prayer-Galetti T, Rossi GP, Belloni AS. Gene expression and autographic localization of endothelin-1 and its receptors A and B in the different zones of the normal human prostate[J]. J Urol,1997,157:2334-2339
[25]Peehl DM, Cohen P, Rosenfeld RG. ReviewThe insulin-like growth factor system in the prostate[J]. World J Urol,1995,13(5):306-11
[26]Grant ES, Ross MB, Ballard S,et al.The insulin-like growth factor type I receptor stimulates growth and suppresses apoptosis in prostatic stromal cells[J]. J Clin Endocrinol Metab,1998,83(9):3252-3257
[27]KroemerG, Petit P, Zalnzami N, et al.The biochemistry of Progralnmed cell death[J]. FASEB J,1995,9:1277-1287
[28]Nagata S, Golstein P. The Fas death factor[M], Science,1995,267:1449-1456
[29]Enarlm, Hug H,Nagata S.Involvem ent of an ICE-ltke protease in Fas-mediated apoptosis[M].Nature,1995,375:78-81
[30]Seino K, Kayagai N, Fukao K, et al. Rejection of Fas ligand. expressing grafts [J]. Tans Proc,1997,29:1092-1093
[31]谢庆祥,汪鸿,缪友仁等.细胞凋亡相关基因bc1-2和bax在前列腺增生组织中表达的意义[J].中华泌尿外科杂志,1998,19(1)：98-100
[32]魏红山,李定国.细胞凋亡的信号转导机制与调节[J].国外医学分子生物学分册,2000,22(1)：27-31
[33]暨明,韦超凡.细胞凋亡启动与执行分子极其作用机制的研究进展[J].国外医学·生理、病理科学与临床分册,2001,21(2)：92-94
[34]Lee J, Richburg JH, Younkin SC et al.The Fas system is a key reguIator of germ cell apoptosis in the testis[J]. Endocrinology,1997,138(5):2081-2088.
[35]Kawakami A, Eguehi K. Involvement of apoptotic cell death in autoimmune diseases [J]. MedElectron Mierose,2002,35(1):1-8.
[36]Philchenkov AA. CasPases as regulators of apoptosis and other cell functions [J]. Bioehemistry(Mose),2003,68(4):365-376.
[37]郑佳,刘复强Fas/Fasl及其临床意义[J].首都医科大学报,2004,25(3)：411-414
[38]Ligand F. A Death factor and its receptor[J]. Adv Immunol,1994,57:129-144
[39]杨金瑞,黄循.前列腺疾病细胞凋亡及Bcl-2/Bax, Fas/Fasl调控研究[J].国外医学·泌尿系统分册,2000,20(4)：149
[40]谢庆祥,汪鸿.前列腺组织中细胞凋亡调控基因的表达[J].临床泌尿外科杂志,2000,15(7)：320-321
[41]曹继刚,周安方,舒劲松,等.仙甲汤对实验性前列腺增生大鼠前列腺组织FAS蛋白表达的影响[J].现代中西医结合杂志,2008,17(6)：823824
[42]段登志,于玲,张鸿青,等.前列回春对实验性大鼠前列腺组织Fas表达及细胞凋亡的影响[J].中国中药杂志,2003,(28)9：866-869
[43]Sasaki Y, Ahlned H. Takeuehi T, et al. Immunohistoehemical study of Fas. Fas ligand and inter leukin-1 converting enzyme expression in human Prostatic cancer [J].Br J Urol,1998,81:852-855
[44]EmiInui, AtushiQchiai, YoshiNaya, et al. Comparative morphometric study of bladder detrusor between patients with benign prostatic hyperplasia and controls [J].J Urol,1999,161(3):827-830
[45]黄旭元,易彬,陈斌,等.BPH患者膀肤逼尿肌细胞凋亡及Fas、Fasl表达的研究[J].中国男科学杂志,2005,19(6)：18-20
[1]Aggarwal S, Thareja S, Verma A, Bhardwaj TR, Kumar M. An overview on 5alpha-reductase inhibitors[J]. Steroids,2010,75(2)：109-153
[2]Suzuki K, Ito K, Ichinose Y, Kurokawa K, et al. Endocrine environment of benign prostatic hyperplasia:prostate size and volume are correlated with serum estrogen concentration[J]. Scand J Urol Nephrol,1995,29(1):65-68.
[3]张玉海,邵强.前列腺外科[M].北京：人民卫生出版社,2001,104-108
[4]张熙,贺菊乔,刘丽芳.前列散瘀胶囊治疗前列腺良性增生症的实验研究[J].湖南中医药导报,2004,10(1)：49-50.
[5]段登志,于玲,陈黎明.前列回春胶囊对实验性大鼠前列腺组织T、DHT含量的影响[J].新中医,2003,35(11)：75-76.
[6]曾宪彪,韦宝伟,李茂.前列通软胶囊对实验性大鼠前列腺增生和前列腺炎的影响术[J].中国现代医药,2007,9(10)：12-13.
[7]周建衡,洪振丰,林久茂.前列宁颗粒对大鼠前列腺增生的影响[J].福建中医学院学报,2008,18(5)：45-47
[8]张亚大,卢子杰,张平,等.益肾逐瘀汤治疗良性前列腺增生症100例疗效观察及对性激素的影响[J].新中医,2003,35(9)：14-15
[9]管家齐,宋捷民,陈海委,等.桂枝茯苓丸与桂枝水煎剂对前列腺增生小鼠影响的实验研究[J].中国中医药科技,2008,15(4)：259-260
[10]姚良权,李顺民,郭跃华,等.补骨脂素对大鼠前列腺增生治疗作用及对前列腺细胞雌雄激素受体的影响[J].北京中医药大学学报,2005,12(4)：8-10
[11]袁庆东,肖向茜,梁承.电针用于治疗大鼠实验性前列腺增生症的机制研究[J].中国康复医学杂志,2008,23(6)：532-534
[12]Kojima Y, Hayase M, Imura M, etal. The role of alphal-adrenoceptor subtypes in benign prostatic hyperplasia-from bed to bench[J]. Hinyokika Kiyo,2008,54(6):4 57-462
[13]Andersson KE. Alpha-adrenoceptors and benign prostatic hyperplasia:basic principles for treatment with alpha-adrenoceptor antagonists[J]. World J Urol, 2002,19(6):390-396
[14]郭应禄,胡礼泉.男科学[J].北京：人民卫生出版社,2005,1494
[15]张蜀武,常德贵,王久源,等.通关胶囊对离体人增生前列腺α1-AR的拮抗作用[J].中华男科学,2001,7(2)：136-138,140
[16]慈健,刘树民,宫大鑫,等.前列安栓对慢性前列腺炎和良性前列腺增生症患者尿流率的影响[J].中国男科学杂志,2003,17(2)：129-130
[17]席建元,贺菊乔,张熙,等.前列散瘀胶囊治疗良性前列腺增生的临床观察[J].中华男科学杂志,2005,11(1)：68-69,75
[18]许国振,崔金涛.决闭胶囊与保列治抗实验性前列腺增生作用的比较研究[J].中国中医药科技,2003,10(1)：9-10
[19]刘巧格,贾晓明,王生茂,等.尿通胶囊治疗老年前列腺增生症临床及实验研究[J].河北中医,2002,24(6)：403-407
[20]Soulitzis N, Karyotis I, Delakas D, et alExpression analysis of peptide growth factors VEGF, FGF2, TGFB1, EGF and IGF1 in prostate cancer and benign prostatic hyperplasia[J].Int J Oncol,2006,29(2):305-314
[21]De Bellis A, Ghiandi P, Comerci A, et al. Epidermal growth factor, epidermal growth factor receptor, and transforming growth factor-alpha in human hyperplastic prostate tissue:expression and cellular localization[J]. J Clin Endocrinol Metab, 1996,81(11)：4148-4154
[22]席建元,贺菊乔,周亮.前列散瘀胶囊对实验大鼠血清NO, bFGF影响的实验研究[J].新中医,2006,38(8)：89-90
[23]周亮,袁轶峰,贺菊乔.前列散瘀胶囊对实验性大鼠前列腺增生组织中碱性成纤维细胞表达的干预[J].中医药导报,2006,12(5)：65-66
[24]张凯,杨新宇,张军,等.泽桂癃爽胶囊治疗良性前列腺增生疗效和作用机理的初步研究[J].中华泌尿外科杂志,2003,24(6)：388-390.
[25]鲁会侠,张晓红,岳媛.前列舒通胶囊对实验性前列腺增生的作用[J].中国中西医结合外科杂志,2007,13(2)：155-158
[26]李翠英,周亮,贺菊乔.前癃通胶囊对体外培养基质细胞TGF-β1表达干预作用的研究[J].中国中医药科技,2005,12(2)：75-76
[27]蔡文清,黎玮,张勇.中药方剂Ⅰ号对小鼠前列腺细胞碱性成纤维细胞生长因子以及转化 生长因子-β1表达的影响[J].中华实验外科杂志,2007,24(7)：867-868
[28]贾金铭,马卫国,焦拥政.癃必消胶囊对体外培养的人前列腺增生间质细胞作用机制的实验研究[J].中国中西医结合杂志,2009,29(1)：55-58
[29]段登志,张鸿青,于玲.前列回春对实验性大鼠前列腺组织血.管内皮生长因子表达的影响[J].中华男科学,2004,10(2)：152-154
[30]Wang L, Yang JR, Yang LY, et al. Expression of Ki-67, Bcl-2, Bax and caspase-3 in benign prostatic hyperplasia combined with prostatitis and their significances[J]. Zhongnan Daxue Xuebao Yixueban,2008,33(3):222-226
[31]Iacopino F, Angelucci C, Lama G, et al. Apoptosis-related gene expression in benign prostatic hyperplasia and prostate carcinoma[J]. Anticancer Res,2006, 26 (3A):1849-1854
[32]Angelucci C,Iacopino F, Lama G, et al.Reverse transcriptase-PCR analysis of apoptosis-regulating gene expression in human benign prostatic hyperplasia[J]. Anticancer Res,2005,25(6B):3937-3941
[33]席建元,贺菊乔,周亮.前列散瘀胶囊对实验大鼠前列腺基底细胞凋亡的影响[J].江苏中医药,2005,26(10)：66-68
[34]黄源鹏,杜建,洪振丰.康泉方对大鼠前列腺组织凋亡调控基因bax、bcl-2 mRNA表达的影响[J].中国中西医结合杂志,2007,27(8)：711-712
[35]杨金瑞,黄循.前列腺疾病细胞凋亡及Bcl-2/Bax, Fas/Fasl调控研究[J].国外医学·泌尿系统分册,2000,20(4)：149
[36]段登志,于玲,张鸿青,等.前列回春对实验性大鼠前列腺组织Fas表达及细胞凋亡的影响[J].中国中药杂志,2003,(28)9：866-869
[37]曹继刚,周安方,舒劲松,等.仙甲汤对实验性前列腺增生大鼠前列腺组织FAS蛋白表达的影响[J].现代中西医结合杂志,2008,17(6)：823-824
[38]陈通文,邓春华,刘建中,等.前列通瘀提取液对前列腺平滑肌细胞增殖与凋亡的作用[J].中华医学研究杂志,2005,5(7)：626-627
[39]杨胜兰,曹继刚,周安方.仙甲汤对实验性前列腺增生大鼠前列腺组织细胞核增殖抗原表达的影响[J].华中科技大学学报(医学版),2006,35(3)：413,415
[40]Gradini R, Realacci M, Ginepri A, et al. Nitric oxide synthases in normal and benign hyperplastic human prostate:immunohistochemistry and molecular biology[J]. J Pathol,1999,189(2):224-229
[41]Bloch W, Klotz T, Loch C, et al. Distribution of nitric oxide synthase implies a regulation of circulation, smooth muscle tone, and secretory function in the human prostate by nitric oxide[J]. Prostate,1997,33(1):1-8
[42]贾金铭,马春涛,王勒渝,等.消癃通闭对前列腺平滑肌中NOS神经的影响[J].现代泌尿外科杂志,2001,6(2)：12-15
[43]候士良,许伏新.三妙胶囊治疗前列腺增生药理研究[J].中国中药杂志,2000,25(2)：110-114
[44]马卫国,贾金铭.中西医结合诊疗良性前列腺增生症的思路[J].中国男科学杂志,2009,23(4)：1-2